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ABSTRACT 
 
The aims of this study were to develop polymeric NP formulations for triamcinolone 
acetonide (TA) delivery, from biodegradable and biocompatible hydrophobic 
polymers, which provide sustained release, prolonged stability and low toxicity, and 
to assess the toxicity of TA NPs (TA-NPs) compared to TA alone upon BALB/c 3T3 
and ARPE 19 cell culture models. 
 
The study involved investigation of three different types of polymers: 
poly(D,L,lactide) (PDLLA), poly(D,L,lactide-co-glycolide)(PLGA) and methoxy-
polyethyleneglycol poly(D,L,lactide-co-glycolide)(mPEG PLGA). Two different 
methods were studied in the TA-NPs preparation: spontaneous emulsification solvent 
diffusion and emulsification solvent evaporation methods.  
 
The results show that emulsification-solvent evaporation method was superior to 
spontaneous emulsification solvent diffusion in terms of yield, loading and 
entrapment efficiency. TA-NPs synthesised of mPEG PLGA exhibited the smallest 
particle size, highest efficiency and fastest release of TA, whereas PDLLA produced 
large TA-NPs with the slowest TA release. The toxicity study revealed that BALB/c 
3T3 was more sensitive than ARPE 19 and was concentration dependent in response 
to  24 hour exposure of either TA or TA-NPs, while ARPE 19 appeared to be less 
sensitive to the exposure. All NPs were less toxic than TA in all concentrations, in 
both cell models.  
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INTRODUCTION 
 
1.1 Sustained/controlled release systems 
The main challenge of developing a successful drug delivery system is to deliver the 
drug promptly to the target site at a rate and a concentration which can maximise the 
efficacy and minimise the side effects, in a appropriate period of time 1. Several 
parameters, such as bioavailability, biocompatibility, site targeting and drug release 
profile, play a dominant role in administering the drug 2. Although conventional 
formulations have been effective for most of the drugs, there have been obstacles for 
some  drugs to achieve the target site, due to poor physicochemical properties and an 
incapability to pass through the barriers of the body. Such drugs, especially those 
which have a narrow therapeutic range and exhibit poor solubility but require  long 
term and localised therapy, would need a continuous administration to maintain the 
plasma level in the therapeutic range over a period of time 3. In addition, patient non-
compliance with the required administration of the drugs appears to be a significant 
problem 1. Therefore, several modifications to drug delivery, such as designing 
sustained or controlled release products, were made, in order to control frequency of 
dosing and specificity of the drug. This can lead to improved patient     compliance 1, 
4, 5.  
 
Sustained release (a term that can be interchangeably used with prolonged release 1) 
products have been developed commercially since the late 1940s 6 with the aims of 
minimising the frequency of administration as well as side effects, locally or 
systematically. Although sustained release products can enhance patient compliance, 
these products were only set up with the goal of prolonging the therapeutic duration 
without any consideration of consistency in terms of drug release.  In the late 1960s,  
the term “controlled release” was used to describe a system which could release the 
drug in a reliable and constant release fashion 6. By establishing such strategies as 
controlling the drug released, modifying the methods to reach the target, and 
maximising the extent of drug concentration on the target site, the drug efficacy 
could be improved in a controlled release system.  
 
 2
1.2 Nanoparticles (NPs) 
Over the past two decades there has been a variety of controlled drug delivery 
strategies used to enhance the efficacy of the drug, such as developing soluble 
macromolecular carriers, micellar carriers, and colloidal micro- and nanoparticulate 
carriers. Those approaches, especially micro- and nanoparticulate carriers, have 
become extremely valuable in altering the pharmacokinetic and pharmacodynamic 
properties of the drug.  
 
Among the various colloidal particulate systems, NPs have attracted much interest in 
the development of controlled delivery systems. Kreuter 7 defined NPs as “solid 
colloidal particles ranging in size from 10 nm to 1000 nm (1µm)”.  The drug can be 
entrapped in, encapsulated in, dissolved in, adsorbed or chemically attached to, the 
matrix of the NPs, which can be polymers or lipids.  
 
Since this study will mainly focus on polymeric NPs, only the criteria, characteristic 
and therapeutic application of polymeric NPs (thereafter referred to as ‘NPs’ ) will be 
reviewed in the following sections.  
 
By incorporating the drug into the polymer matrix and reducing the particle size 
down to nano-scale, the nature of the drug and its interaction with biological 
membrane can be modified, leading to the improved delivery of the drug to the target 
site, which is facilitated by a controlled release.  NPs can protect the drug from the 
unfriendly environment thereby avoiding premature degradation of the drug 8. NPs 
are reported to be more stable than liposomes 9. This delivery system was also 
reported to be able to minimise the local side effects as well as systemic ones 10.  
Moreover, NPs can be an exclusive controlled delivery since it can be bound with the 
specific ligand for targeting drug actions 11-13.  
 
NPs can be further distinguished as nanospheres and nanocapsules. The illustration 
can be seen in Figure 1.1. In nanospheres, drugs are dispersed in the matrix structure 
as a uniform dispersion, whereas nanocapsules are vesicular systems in which the 
drug can be dissolved or entrapped in the inner core or adsorbed onto the surface of 
inner vesicles 9.  
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Figure 1.1: Nanospheres and nanocapsules 14.  
 
Compared to microparticles, NPs show significant advantages in site-specific drug 
delivery. It has been suggested that, for intravenous administration, the particle 
should be smaller than 8 µm to avoid capillary clogging 3.  In addition, since the 
diameter of the capillaries is about 5-6 µm, the carriers should be a much smaller 
size, so they can be delivered without showing any harmful effects for the blood 
circulation system, such as embolism in the capillaries 12. NPs also show higher 
intracellular uptake 9. NPs synthesised from surface modified polymer, are reported 
to be able to enhance prolonged blood circulation and pass through the blood-brain 
barrier 12, 13, therefore, they are potentially useful as an optimised delivery system to 
intravascular administration.  
 
1.2.1 Criteria of ideal NPs 
As a drug carrier system, a nanoparticle (NP) formulation should meet the main 
criterion, in which the matrix should be biocompatible and biodegradable 3, 15. The 
matrix must be non-toxic and must not exhibit any antigenic behaviour to the body 3, 
16. Oppenheim 17 and Domb 18 emphasised that for an ideal drug carrier system, the 
matrix of the product should be stable during the sterilisation and manufacturing, to 
enzyme activity, the pH of the environment and must not be degraded in a short 
period of time and it should provide sustained release. Moreover, the NPs should be 
able to load the drug, which is either hydrophilic or hydrophobic in nature, in a 
sufficient amount and maintain the integrity of the drug-matrix before release of the 
drug at the target site. The matrix, should therefore, protect the drug until it reaches  
the target site. Finally, the system should provide a reliable and reproducible release 
kinetics for the drug in a controlled fashion 17. In terms of drug-carrier production, 
the cost-effective and reproducibility of the manufacturing of the drug-carrier 
complex should also be taken into consideration 18.  
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1.2.2 Limitation of NPs 
Much research has been conducted on nanoparticulate system, however it is still in 
an ongoing process to establish the formulation which is pharmaceutically and 
clinically accepted. Controlling the particle size has always been a challenge in 
developing NP formulations. Although nano-sized particles can be easily made by 
various methods of NP preparation, the physical stability of NPs, mainly the particle 
size, sometimes cannot be maintained due to the potential risk of particle 
aggregation. NPs can load either hydrophilic or hydrophobic drugs, however, the 
level of loading appears to be low, compared to microparticles. In terms of release 
characteristic, NPs have potential to undergo an initial burst release due to drug 
adsorption on the particle surface during manufacture. This initial burst release may 
lead to toxicity if the concentration of drug released is over the minimum level of 
toxic concentration (MTC) in the blood. In terms of toxicity issue, the various 
interactions of NPs with biological tissues have to be taken into consideration. NPs 
may trigger mediator to activate inflammatory or immunological responses. If it is 
administered intravenously, they may have potential to affect the cardial and cerebral 
function 19. Despite those limitations, modification and innovation have been 
extensively developed in order to optimise the NPs formulations.  
 
1.2.3 Potential pharmaceutical applications of NPs 
NPs can be used to deliver various drugs, such as hydrophilic drugs 20, hydrophobic 
drugs,  peptides, and vaccines 21 in prolonged period time of circulation. They can 
also be targeted carriers in the lymphatic system, brain, arterial walls, lungs, liver, 
and spleen 12.  
 
Gene therapy 
NPs have been investigated in clinical phase I of cysctic fibrosis therapy 22.  This 
investigation aimed to provide a single molecule gene of the cystic fibrosis 
transmembrane regulator (CTFR)  in ultra small NPs (less than 25 nm) to slip 
through the nuclear membrane. The use of poly-L-lysine was reported to be in 
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association with reduced size, enabling internalisation of the gene to eventually reach 
the nucleus. 
 
Ocular therapy 
In ocular therapy, there have been several investigations involving NPs. Pilocarpine 
NPs has been reported as the first NP formulation in ocular delivery 23. 
Polymethylmetachrylate was employed to prepare the NPs. This study demonstrated 
that Piloplex system decreased the intra-ocular pressure in clinical trials.  
The efficacy of cyclosporin in nanocapsules was investigated by Calvo et al 24 as a 
comparison with oily solution cyclosporine. They revealed that there was corneal 
level induction five times higher than control. Campos 25 demonstrated the potential 
NP delivery of cyclosporine A in the eye using chitosan.  
 
Cancer chemotherapy 
In cancer chemotherapy, NPs were reported as promising carriers for anticancer 
agent such as doxorubicine 26, paclitaxel 27-29, peptides, and antiangiogenic genes. 
 
Mu et al 30 demonstrated the manufacturing of PLGA nanospheres to deliver 
paclitaxel, a potent anticancer agent. Due to the poor solubility of paclitaxel, the 
formulation of this drug needs to be improved. In this study, Mu et al 30 also 
introduced the use of vitamin E TPGS as the stabiliser. Since vitamin E TPGS is 
natural and non toxic, no stabiliser removal was needed. This feature can be 
potentially valuable for NP formulation.  
 
Research has been carried out in the development of antiangiogenesis therapy using 
NPs 22, 31. This therapy aims to interrupt the blood supply for the tumors by 
diminishing the blood vessels around the tumors. However toxicity issues increase as 
the agent may not be selective to the tumor blood vessels; but may affect the normal 
vessels. NPs are thought to be a promising targeting delivery system to address this 
issue, since they can couple the antiangiogenic ligand, and, due to their small size, 
the NPs will be able to deliver the agent precisely and specifically into local 
endothelial cells 32.  
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Vaccine delivery 
Singh et al. 33 demonstrated the manufacture of poly-(ε-caprolactone) (PCL), a 
poly(lactide-co-glycolide) (PLGA)-PCL blend and co-polymer NPs encapsulating 
diphtheria toxoid (DT) for a mucosal vaccine delivery system. Significantly higher 
uptake of PCL NPs was observed in an in vitro experiment using Caco-2 cells in 
comparison to polymeric PLGA, the PLGA-PCL blend and co-polymer NPs. 
Positive correlation between hydrophobicity of the NPs and the immune response 
was also observed following intramuscular administration and after intranasal 
administration of the NPs.  
 
Immunopotentiation effect at modest doses of a few micro- or nanograms of CpG 
oligodeoxynucleotide (CpG ODN) and the influence on T cell responses at such low 
doses has also been investigated to establish NP delivery of vaccine adjuvant of 
tetanus toxoid. This study emphasises that antigen delivery in biodegradable NPs can 
facilitate the induction of strong T cell responses, particularly of the Th1 type, at 
extremely low doses of CpG ODN since NPs have an immunopotentiation effect on 
T cell response. This dose modification would be beneficial for minimising the 
potential side effects of these novel adjuvants 34. 
 
1.2.4 Polymers used for NPs manufacturing 
A large variety of polymers can be employed as matrix materials of the NPs to 
provide a controlled release effect.  They are categorised as biodegradable and non-
biodegradable polymers. Since the current study involves biodegradable polymers, 
which have potential value in a controlled drug delivery, this review will mainly 
focus on those polymers.  
 
Biodegradable polymer is a polymer which can be metabolised either enzymatically 
or non enzymatically in vivo, to produce biocompatible by-products, which then can 
be eliminated by normal physiological pathways 35. Biodegradable polymers have 
shown several advantages over non-biodegradable polymers. Once they were 
implanted, the biodegradable polymers do not need surgical removal from the body. 
They are degraded over time in a controlled decay, in which the side effects on the 
tissues can also be decreased 36. However, biodegradable polymers also have a 
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limitation as they are difficult to remove in the case of therapy rearrangement. In 
terms of safety, monitoring of the reaction affected by the degradation products must 
also be carried out  3, 37.  
 
In addition to biodegradability, other properties of polymer such as crystallinity and 
glass transition temperature are also important considerations in selection of a 
polymer for NP formulation. In terms of crystallinity and glass transition temperature 
(Tg), polymers can be divided as glassy polymers (Tg > 37ºC) and rubbery polymers 
(Tg < 37ºC).  The glass transition temperature is associated with the permeability of 
the polymers. The permeability will increase with the decrease of the Tg. To achieve 
sufficient permeability, an approach to decrease the Tg can be applied by the addition 
of methylene groups to the backbone of the polymer structure, as well as introducing 
an asymmetric center. Increasing the crystallinity as well as Tg, however, can be 
carried out by the addition of aromatic groups to the polymer backbone. This 
manipulation aims to increase the mechanical strength of the polymer since the ideal 
matrix should be soft and pliable (Tg < 37ºC) but should maintain the tensile strength 
afterwards 3.  Chawla et al 38 demonstrated that microchannel structures are formed 
in a highly crystalline matrix, resulting in a high effective area for drug diffusion.  
 
Natural hydrophilic polymers 
Natural hydrophilic polymers have been reported to be potential matrices for 
encapsulating the drug in NPs. They are divided into two major categories: proteins 
(albumin and gelatine) and polysaccharides (alginate, dextran, chitosan). 
 
Chitosan, as an example of natural hydrophilic polymers, is synthesised from chitin 
deacetylation 25, 39-41. It has been widely used as a carrier in controlled delivery 
systems. Chitosan is a cationic polymer and due to a strong positive surface charge, it 
can be well adhered with a negatively charged surface and chelates metal ions 42. 
This polymer may potentially be applied for developing the delivery of cyclosporine 
A to the cornea and conjuctiva, due to its ability to remain attached onto the surface 
for at least 24 hours 25 and also development of vaccines delivery 40, 41.  
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However, natural polymers have been reported to have less capability to provide the 
range of ideal characteristics to be such carriers in a controlled release study, since 
they may degrade the drug embedded because of required cross-linking, they are 
sensitive to microbial growth and enzymatic degradation 12 and they may induce 
immune response 43. Therefore, synthetic hydrophobic polymers have been 
extensively investigated as alternative drug carriers in the manufacturing of NPs. 
 
Synthetic hydrophobic polymers 
Synthetic hydrophobic polymers have attracted much attention in developing the 
nanoparticle (NP) formulation. They offer advantages in that they are biocompatible 
and can be relatively good carriers without showing undesirable interaction with the 
drug. Although they degrade over time, there is no report of microbial or enzymatic 
activities involved in the process of degradation. Of those polymers, only poly (D,L,-
lactide) and poly (D,L,-lactide-co-glycolide) (PLGA) will be reviewed, since those 
polymers were used in the current study. Those polymers have been widely 
investigated as drug carriers since they are biodegradable and biocompatible 
therefore they have regulatory approval in most countries. Toxicological and clinical 
data of those polymers is readily obtainable. Moreover, those polymers are 
commercially available  43, 44. 
 
Poly (D,L,-lactide) (PDLLA) 
PDLLA is completely amorphous with a glass transition temperature of around 57ºC. 
Since it is more amorphous than the other isomer, poly (L-lactide) (PLLA), the 
tensile strength as well as the modulus of elasticity of this polymer are lower, ~5000 
psi and ~250,000 psi respectively. The consequence of this characteristic is that this 
polymer will be degraded faster than PLLA 45.  The group of lactic acid indicates that 
the poly lactic acid  is hydrophobic (Figure 1.2) with a level of hydrophobicity 
greater than Poly(D,L,lactide-co-glycolide) but less than poly(L, lactide). 
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Figure 1.2: Structure of poly (lactic acid)43. The letter n represents the number of 
lactic acid monomers  
 
Poly (D,L,-lactide-co-glycolide) (PLGA) 
PLGA has been clinically approved by the FDA as a biodegradable and non-toxic 
polymer46. This polymer was initially applied as a suture, which did not require 
surgical removal on its application. Its advantages, such as excellent 
biodegradability, biocompatibility, mechanical strength, hydrophobicity and 
flexibility, make this the most commonly used polymer in a controlled delivery 
system.     
 
PLGA is synthesised by polymerisation lactide/glycolide in various ratios. PLGA is 
copolymer of poly(lactide) (PLA) and poly(glycolide) (PGA), which can be well-
absorbed into the body when it is degraded. The chemical structure of PLGA can be 
seen in Figure 1.3. Gurny15 suggested that the rate of PLGA biodegradation 
increased with increasing the glycolic unit proportion in this polymer. 
 
 
Figure 1.3: Structure of poly (D,L, lactide-co-glycolide) 43. The letter p represents 
the number of glycolic acid monomer, q represents the number of lactic acid 
monomer 
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1.2.5 Synthesis of NPs 
A variety of methods have been developed to synthesise NPs. Those methods can be 
classified based on the performed matrix polymers, whether they are from the 
monomer which undergoes polymerisation or directly from the macromolecules. In 
this review, the most important methods of NPs preparation are described. 
  
Coacervation/phase separation 
Coacervation/phase separation techniques can be separated into two categories: 
aqueous phase separation and organic phase separation. The basic principle of this 
method is the addition of desolvating agent which can decrease the solubility of the 
matrix, leading to phase separation. In this separation, polymer and coacervates exist 
in one phase, and free-polymer-supernatant is in the other phase.  
 
Solvent diffusion (nanoprecipitation or solvent displacement) 
method 
The solvent diffusion method has been very popular in the preparation of NPs in 
recent years. Chorny 47 reported that this method can produce NPs sized less than 
100 nm with a narrow distribution using several modifications. This is suitable to the 
preparation of highly-intracellular uptake-NPs. Another advantage of this method is 
that the method requires relatively non-toxic organic solvents, such as acetone, or a 
mixture of acetone and ethanol; therefore the risks of potentially toxic solvents can 
be avoided 47-49. High energy output equipment can also be avoided using this 
method, leading to the possibility for this method to be scaled up 50. 
 
The principle of this method is a precipitation of polymer or drug with polymer in the 
form of NPs as a result of rapid diffusion of one or two miscible organic solvents, in 
which polymer or a combination of polymer and drug, were dissolved into water.  
The basic procedure was a dropwise addition of the polymeric organic solution into 
an aqueous solution containing a stabiliser and followed by continuous stirring at 
room temperature to reach equilibrium.   
 
Murakami et al.48 established a modified spontaneous emulsification solvent 
diffusion method. In this development, they suggested that a proper composition of 
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binary organic solvents (ethanol and acetone) and the polymer concentration can 
present NPs with better characteristics, such as submicron particle size and higher 
yield efficiency (Figure 1.4).  In their experiment, ethanol added to a PLGA acetonic 
solution, was also shown to inhibit the aggregation. 
 
 
 
 
Figure 1.4: Solvent diffusion process illustrated by Murakami 48 
 
The mechanism involved in the solvent diffusion method can be explained by a study 
reported by Murakami et al 48, 49. In their study of developing a modified spontaneous 
emulsion solvent diffusion, they introduced a mixture of two organic solvents, which 
were ethanol and acetone. They demonstrated that there was a perturbation of the 
interface during the dispersion of PLGA solution into the aqueous PVA solution, 
leading to the spontaneous formation of a large interfacial area. This phenomenon 
was governed by the so called Marangoni effect, resulting in nano-sized quasi 
emulsion droplets of PLGA solution. The ethanol initially diffuses out from the 
droplet due to the lower affinity of ethanol to PLGA, followed by acetone. Acetone 
subsequently diffused, resulting in PVA coacervation in the aqueous phase. This 
diffusion allowed an increased concentration of PLGA, leading to the solidification 
or precipitation of PLGA and PVA adsorption simultaneously. This spontaneous and 
instantaneous process allowed the formation of uniform NP dispersion under mild 
agitation. 
 
Regardless of the advantages described above, several disadvantages have also been 
uncovered, such as less drug load due to leakage (especially for hydrophilic drugs) or 
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crystallisation of the drug (for hydrophobic drugs) during the process, and less yield 
due to initial aggregation of the polymer and the physical instability of the NPs.   
 
Emulsification-solvent evaporation 
This method involves organic solvents which are immiscible with water.  
Emulsification-solvent evaporation has been successful in encapsulating the drug to 
produce NPs as well as microparticles, of either hydrophilic or hydrophobic drugs. 
The ability to load higher amounts of the drug, especially the hydrophobic drugs or 
drugs with poor solubility, indicates this method is superior to the solvent diffusion 
method.  However, the use of potentially toxic solvents should be taken into 
consideration. The appropriate solvent removal method should be carried out 
following this method of NP preparation.  
 
The mechanism of solvent evaporation is different from solvent diffusion. The 
reduction of particle size is not governed by organic solvent diffusion, but by a 
vigorous agitation in the formation of primary emulsion droplets. The organic 
solvent of this method is subsequently removed by evaporation after a formation of 
emulsion droplets 12. Increasing the energy of agitation results in the smaller 
particles. To achieve nano-sized particles, therefore, the aid of sonication is needed.  
 
This method does not only allow the hydrophobic drugs  to be encapsulated, but also 
hydrophilic drugs, by employing water - in oil - in water (W/O/W) emulsion 51. 
Basically, the hydrophilic drug is dissolved in the aqueous phase, then it is 
emulsified with an organic solvent containing polymer. This emulsion is then 
emulsified with aqueous phase containing the stabiliser. By this process, the 
hydrophilic drug should be well encapsulated in a polymer matrix. The oily phase 
will prevent the drug to diffuse to the external aquoeus phase. Solidified NPs are then 
produced by removing the organic solvent and it is followed by the drying procedure 
to collect the dry, solid NPs. 
 
1.2.6 Surface modification of NPs 
Conventional hydrophobic NPs in blood circulation may be prone to the rapid 
clearing by opsonisation and macrophages. Therefore, considerable effort has been 
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made in order to prevent the NPs from early clearing and to prolong the circulation in 
the blood. It is suggested that to prevent phagocytosis, particles should be larger than 
3 µm 3. However, this suggestion apparently does not work in NP development.  
 
Surface modification has been developed to tailor the problem 9.  Coating the surface 
with hydrophilic polymers allows the hydrophobic NPs to be retained longer in the 
circulation due to steric stability offered by hydrophobic polymer. This approach 
may also control the opsonisation and improve the surface properties of the NPs. 
Among those surface coated polymers, PEGylated-poly lactide (methoxy poly lactide 
mPEG PLA) and PEGylated PLGA(methoxy-poly lactide-co-glyclide, mPEG 
PLGA) have gained much interest in the NP investigation. Their basic colloidal 
properties and degradation depend on copolymer composition. The mPEG PLA and 
mPEG PLGA NPs exhibit prolonged blood circulation following intravenous 
administration to animals. The composition of NPs determines their biodistribution 
properties, probably through its influence on the effectiveness of the PEG steric 
barrier and the size of the NPs. The ability of the mPEG PLA and mPEG PLGA NPs 
to avoid rapid phagocytosis has extended the range of sites within the body that the 
NPs can reach, which has significant implications with regard to their application in 
controlled drug delivery and targeting. The mPEG PLA and mPEG PLGA NPs can 
be loaded with a variety of bioactive agents achieving satisfactory loading, especially 
in the case of hydrophobic drugs. The NPs have been investigated for the treatment 
of infectious diseases and cancer, the intravenous and mucosal delivery of proteins, 
and oligonucleotide and gene delivery 52-54. This current study is investigating mPEG 
PLGA as one of the polymers used in nanoparticle formulations. The chemical 
structure of mPEG PLGA is shown in Figure 1.5. 
 
Figure 1.5: Structure of (methoxypolyethyleneglycol)poly-(D,L,lactide-co-
gycolide)13 
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1.2.7 Physical characterisations of NPs  
To characterise the NPs, there are mainly five parameters to be taken into 
consideration: particle size and morphology of particles, surface charge, drug loading 
and release study. 
 
One of the most important features of NPs is particle size. It has been a challenge in 
NP formulation to measure the particle size accurately in the presence of dust, 
microbial contamination and crystallisation or aggregation of the ingredients that 
occur during the synthesis. However, photon correlation spectroscopy or dynamic 
light scattering is the currently applicable method to measure the size of sub-micron 
particles. It measures the hydrodynamic diameter which is a combination of the 
particle diameter and the double layer thickness. This method offers several 
advantages: it enables small and non-invasive sampling, automatic measurement, and 
is less time-consuming with high accuracy results. The basic instrumentation of this 
method is a coupling between low-angle laser light scattering and a detector in which 
the scattered waves travel to the detector. It is suitable to measure the size of 
particles which undergo a diffusive Brownian motion. Nevertheless, there are several 
drawbacks to be taken into consideration. This method has a limitation of 
measurement up to 3µm. Larger particles are subject to laser diffraction 55. The 
measurement of particle size is normally verified by the examination of the surface 
morphology of NPs. Scanning electron microscopy enables the researcher to 
investigate the surface morphology of the NPs.   
 
Various parameters were reported to highly affect the particle size in NPs 
preparation. Polymer concentration, internal/external ratio, exchange ratio and 
solvent-polymer interaction, as well as stabiliser type and concentration are several 
important parameters in optimising the NPs size. Increasing polymer concentration 
of organic phase added into a stabiliser solution results in poor dispersability of the 
organic phase due to higher viscous resistance against shear forces during 
emulsification. This will produce larger and heterogeneous droplets, which 
eventually result in larger particles 56, 57. The increased internal/external (organic 
phase/ aqueous phase) ratio may prevent coalescence of droplet due to the larger 
amount of solvent in the organic phase, resulting in reduced size of particles 56.    
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Choi et al 58 demonstrated that if the exchange ratio, the ratio of diffusion from 
solvent to water over diffusion from water to solvent, is increased and the solvent-
polymer interaction parameter is decreased, a small supersaturating region will be 
created, resulting in small NPs. Stabiliser type and concentration also affect the size 
of particles in terms of the ability to stabilise the emulsion during preparation. 
Generally, higher stabiliser concentration is more likely to produce smaller particles. 
However, Sahoo et al 59 suggested that for PVA, the concentration of stabiliser used 
in the NPs preparation should not be higher than 2.5% since PVA is aggregated at 
that concentration and tends to show surfactant activity, leading to the formation of 
larger particles after solvent evaporation. Since those parameters were fixed in this 
study, the difference properties of TA-NPs were mainly because of the nature of the 
polymers.  
 
Surface charge, which can be determined by measuring the zeta potential, is an 
indicator for stability of the NPs in the suspension. As the charge increases, the 
repulsive interactions will be greater to maintain physical stability of a suspension. 
The zeta potential can be measured by laser Doppler anemometry. In addition to 
determining the physical stability of NPs in the suspension, surface charge 
determines the acceptability of the NPs when they are administered in the body, 
regarding the phagocytic uptake of NPs by cells of a reticuloendothelial system 8. A 
value of ± 30 mV is considered as the minimum value of zeta potential to provide a 
physically stable nanosuspension 12. In terms of cellular uptake, negatively charged 
NPs show poor endocytosis while positively charged NPs exhibit rapid 
internalisation and accumulate at high extent 60 
 
Determination of the loading of NPs can be carried out in a direct or an indirect way. 
Direct determination, on the one hand,  is carried out especially for hydrophobic 
drugs, which can be extracted from NPs. On the other hand, indirect determination is 
commonly used to determine the hydrophilic drug.  In this technique, free drug in the 
supernatant is determined and is used to subtract the initial drug added to achieve the 
drug loading in the NPs.   
 
The release characteristics of a drug is one of the major features in NPs due to their 
characteristics as a controlled delivery system. The profile of drug release is 
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markedly affected by several factors, such as physicochemical properties of the drug 
and the polymer, size of the particles, distribution of the drug incorporated into NPs, 
stability and the degradation rate of the polymer, the diffusion coefficient and affinity 
of the drug-polymer matrix8, 61. The drug can be released from the matrix by 
desorption of surface bound drug, diffusion through the matrix or polymer walls, 
erosion of the NPs or a combination of erosion of the matrix and diffusion of drug 8. 
 
1.2.8 Purification of NPs 
NPs produced by the available methods may contain contaminants and not be of 
acceptable purity. Poly(vinyl alcohol) (PVA) solution, which acts as a stabiliser 
solution when is used in high concentration, is potentially toxic and unacceptable for 
vascular administration. Excessive amounts of remaining organic solvent are likely 
to be harmful and potentially carcinogenic. Therefore, removal of those elements is 
important in the manufacture of NP system.   
 
A variety of methods have been investigated for NP purification, including dialysis 
centrifugal device (DCD), tangential flow filtration (TFF) and high-speed 
centrifugation 62. Among those methods, high-speed centrifugation is probably the 
most effective and simple way to collect the NPs and remove the impurities. This 
method is reported to able to remove approximately 90% of PVA from the system 62. 
Although the high centrifugal forces may cause a compaction of NPs, especially for 
the hydrophobic matrix, the compaction still can be redispersed in a reasonable 
manner.    
 
1.3 In vitro cell culture toxicity study 
Cell culture has been widely applied to facilitate in vitro toxicity studies. According 
to Freshney 63, cell culture refers to “cultures derived from dispersed cells taken from 
the original tissue, from a primary culture, or from a cell line or cell strain, by 
enzymatic, mechanical, or chemical disaggregation.” Cell culture is also commonly 
employed for investigating various aspect of cell biology and physiology 64. 
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1.3.1 Significance of cell culture for in vitro study 
Cell culture offers an advantage of precise control of physicochemical environment 
and physiological conditions, which is always kept constant. It is also virtually 
identical and the results are more reproducible compared to in vitro study with 
excised animal tissue, therefore it minimises the use of statistical analysis of 
variance. In terms of economical reasons, cell culture requires less reagent and 
reduce the use of animals than in vivo study, therefore the study can be more cost 
effective. In addition, since cell culture only involve either animal or human cells, 
the ethical issue can be avoided 63, 64.  
 
1.3.2 Assay used for in vitro toxicity studies 
A variety of assays have been extensively applied for in vitro toxicity study using 
cell cultures. Those are categorised into two major classes: (1) a short-term response 
using a measure of viability such as membrane integrity or loss of metabolic 
function, during exposure to potentially toxic materials, (2) a long-term response of 
survival, such as expressing metabolic capacity after exposure. 
 
The cell viability can be referred to membrane integrity of cells after being exposed 
to potentially toxic substances, which is determined by either dye exclusion or dye 
uptake.  Dye exclusion refers to the concept in which viable cells are impermeable to 
several types of dyes, while dye uptake refers to the ability of viable cells to take up   
certain chemicals. 
 
1.3.3 MTT assay 
The MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay 
was initially developed by Mosmann in 1983 65. It involves a reduction of yellow 
tetrazolium salt (MTT), to form insoluble purple formazan crystals.  The cleavage of 
tetrazolium salt to yield insoluble formazan product, which then are accumulated 
within cells, can only be carried out by the mitochondrial dehydrogenase enzyme, 
produced by the active mitochondria of living cells. The purple formazan product can 
be solubilised by detergent, dimethyl sulfoxide (DMSO) or isopropanol and 
quantified colorimetrically.  
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MTT assay is proven as a rapid and convenient assay to determine the cellular 
growth and cell survival. It requires a short period of time of analysis and a simple 
spectrophotometry. Moreover, this method offers high sensitivity and accuracy, since 
it can detect slight changes in cell metabolism. The linearity between cell number 
and absorbance, which can be well established, shows the accurate and direct 
quantification of viable cells and proliferation. This assay is also considered to be 
safer than the other methods, since it does not require radioactive substances 65. 
Moreover, this assay is widely acceptable in toxicity studies, especially for NP 
formulations, with good correlation with in vivo toxicity. 
 
1.3.4 Cell lines as the objects for the current study 
The BALB/c 3T3 cell lines are continuous, immortalised but not transformed cell 
lines which are not tumorigenic in mice 66. They are reported as the cell model used 
in the in vitro toxicity evaluation of genistein glycosides using neutral red uptake 
(NRU) assay 67.    
 
The ARPE 19 cell lines are continuous immortalised cell lines established from 
human retinal epithelial cells. It is derived in 1986 by Amy Aotaki Keen 68 from the 
normal eyes of a 19-year old male who died in a motor vehicle accident.              
Dunn et al 68 demonstrated that ARPE 19 cells showed a rapid growth by passage 5, 
forming cobblestone monolayers, which pigmented after several months.  They 
demonstrated that ARPE 19 has structural and functional properties characterisation 
of RPE cells in vivo, therefore this cell line is invaluable for in vitro studies of retinal 
pigment epithelia. 
 
1.4 Triamcinolone acetonide (TA) 
Triamcinolone was first introduced in 1958 as a potent anti-inflammatory agent. Its 
antirheumatic activity was reported as similar to methylprednisolone, but greater than 
prednisolone 69. TA (9α-Fluoro-11ß, 16α,17,21-tetrahydroxypregna-1,4-diene-3,20-
dione cyclic 16,17-acetal with acetone) was developed as a derivative of 
triamcinolone. It has a molecular weight of 434.5 70.  
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Figure 1.6: Structure of triamcinolone acetonide 71 
 
The 9α-Fluoro group attaches to the steroid ring (Figure 1.6) and governs the 
increase of the anti- inflammatory activity while the insertion of a 16α-hydroxy 
analogue is reported to minimise the mineralocorticoid activity 69.  
 
1.4.1 Physicochemical properties  
TA is chemically prepared crystalline powder with white, or almost white, colour in 
a solid state, with no distinct melting points. Several reports state different melting 
points of TA: 277 ºC, 292 ºC, and 294 ºC 72. The difference is likely due to the 
different polymorph existing for the compound. TA is very slightly soluble in water, 
but soluble in ethanol (1:150), acetone (1:11) and chloroform (1:40). It is very 
soluble in dehydrated alcohol and methanol but sparingly soluble in ethyl acetate73 . 
 
TA is reported to be stable in its solid state. However, Gupta 74 demonstrated that 
aqueous-alkaline and ethanolic solutions of TA are unstable. The degradation of TA 
alkaline and ethanolic solution, which follows pseudo-first order kinetics, is 
governed by oxidative rearrangement of the α-ketol side chain.  He also showed that 
TA solution is more stable at pH values less than 5.5 and minimal degradation 
occurred at pH 3.4. However, it was demonstrated that, above pH 7, the 
decomposition decreased with an increase of the ionic strength. In addition, the 
solution stored at 25ºC was nine times more stable that of at 50ºC. Another study, 
which was conducted by Timmins and Gray 75, also demonstrated that TA follows 
specific acid catalysis at pH 1 to 3, and specific base catalysis at pH 4 to 7 an pH 9 to 
12, with the pH independent region at pH 7-9. The pKa of this drug is only stated in 
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terms of TA phosphate (1.70) 70. As TA does not ionise, no information on the pKa 
of TA is available.  
 
1.4.2 Clinical applications  
As a corticosteroid, TA is known to treat various diseases related to autoimmune and 
allergic conditions. It was first introduced in topical administration, which showed 
better efficacy than other corticosteroids. The effect of TA is mainly related to its 
glucocorticoid action and suppression of inflammatory responses. TA is a drug of 
choice to treat diseases associated with inflammation such as arthritis, given by intra 
articular injection to relieve pain. TA has also been reported to reduce lower back 
and radicular pain. In this treatment TA is administered via epidural injections of a 
microcrystalline TA suspension 69, 71, 76, 77 78. 
 
Recently, TA has been extensively investigated in the treatment of a variety of ocular 
diseases associated with inflammation and neovascularisation 82, 84-90. In its 
application for ophthalmic disease management, TA is a proven anti inflammatory 
agent and an inhibitor of neovascularisation 79. TA is a drug of choice for treatment 
of symphatetic ophtalmia and post cataract surgery inflammation77. TA has also been 
indicated for other ophthalmic diseases such as age-related macular degeneration 
(AMD), diabetic macular edema and foveal telangiectasia82, 83. Its antiangiogenic 
effect is mediated through the mechanism of either alteration of extracellular matrix 
degradation or inhibition of angiogenic growth factors 79-81.  
The angiostatic effect of TA in treating neovascularisation 90, 91, therefore provides 
potential for this agent to be developed as an antiangiogenesis agent, which could be 
useful in the treatment of a range of cancers. 
 
1.4.3 Side effects 
TA may suppress the normal inflammatory responses which may activate the latent 
infection caused by tubercular or fungal. The use of large amount of TA can lead to 
the failure of producing adrenal suppression, diabetes, hypertension and Cushing’s 
syndrome. Prolonged used of TA may develop Chusingoid body changes and 
osteoporosis which is irreversible71. Those side effects are related to high dose 
chronic systemic administration. 
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In ocular therapy, TA in suspension is commonly administered to patients with AMD 
or other retinal diseases via intra vitreal and sub-tenon’s injection 87, 88, 92. However, 
there are several side effects associated with those treatments, such as increasing the 
intraocular pressure (IOP) and the risk of post injection infectious endophthalmitis.  
 
TA is commercially available as a cream or gel for topical administration and a 
microsuspension for parenteral administration. In ocular therapy, a suspension of TA 
is commonly administered to a patient with retinal diseases via intra vitreal and sub 
tenon’s injection 82, 88, 93, 94. However, there are several side effects associated with 
those treatments, such as: increasing the intraocular pressure (IOP) and the risk of 
post injection infectious endophtalmitis 92, 95. TA itself is reported as a steroid-
induced risk of ocular hypertension and cataract development regardless of the 
dosage or particle size 77, 92. Other side effects reported are immune system depletion, 
moon face, and osteoporosis 77, associated with high chronic oral doses of 
corticosteroid. Having those potential side effects, the administration of TA should 
be improved to minimize the side effects.    
   
1.5 Objectives of the study  
Over the years, the research focused in our laboratory has been to develop NP 
formulation for delivery of various drugs and peptides.  
 
TA is known as potential anti inflammatory agent and has been extensively 
investigated in the treatment of retinal diseases, such as age related degeneration, 
diabetic macular oedema and neovascularisation 79-83. The ability of TA to inhibit 
neovascularisation can be proposed as a potential indication for TA to be an 
antiangiogenic agent in the cancer chemotherapy.  
 
TA is commercially manufactured as a microsuspension for parenteral 
administration.  Evidence suggests that TA can potentially induce toxicity in that 
form at typical dosages 92. Despite this, there has only been very limited effort 
directed towards to TA formulation to achieve a safer and more acceptable means of 
delivery. Although the delivery of TA by NPs has been investigated by Krause 96, 
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there is a need for further research of TA loaded NPs, using other biodegradable 
polymers and potentially superior methods, to improve the quality of NPs. 
 
The overall aims of this study were to develop TA loaded-NP formulations from 
biodegradable and biocompatible polymers, which provide: sustained release, 
prolonged stability and low toxicity.  
 
In order to achieve the overall aims, the following studies were set up to 
accomplished: 
 Formulation of TA loaded NPs (TA-NPs) using poly(D,L,lactide)  (PDLLA), 
poly(D,L, lactide-co-glycolide) (PLGA) and methoxy-poly-ethylene glycol-
poly(D,L, lactide-co-glycolide) (mPEG-PLGA), 
 Determination of the physical properties of  empty NPs and TA-NPs, 
 Investigation of the effect of NP incorporation on the stability of TA, 
 Investigation of  the effect of polymer on the in vitro release characteristics of 
three different types of TA-NPs,  
 Assessment  of the toxicity profiles of both empty NPs and TA-NPs in two in 
vitro cell culture models: BALB/c 3T3 and ARPE 19. 
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MATERIALS AND METHODS 
 
2.1 Experimental materials 
2.1.1 Experimental materials for TA-NPs formulation 
 Acetonitrile; HPLC grade (LabScan, Thailand); 
 Acetone; HPLC grade (LabScan, Thailand); 
 Boric acid; analytical grade (Ajax Chemical Ltd, Australia) 
 Dichloromethane; HPLC grade (LabScan, Thailand) 
 Di-sodium hydrogen orthophosphate anhydrous (Na2HPO4) ‘AnalaR’; 
analytical grade (Merck Pty.Ltd., Victoria) 
 D,L-Lactide/Glycolide copolymer (PLGA), ratio 85:15, batch number: 
82/136, (Purac Biochem bv, Netherlands) 
 Orthophosphoric acid,  Mw 98.00, BDH ‘AnalaR’; analytical grade, Min 
85% (BDH, Germany) 
 Poly (D,L,-lactic acid)  (PDLLA), lot number: DG 676 GA, (Purac Biochem 
bv, Netherlands) 
 Poly(lactic-co-glycolic)-methoxypoly(ethyleneglycol) (mPEG-PLGA) 
synthesized in house, containing 4.8% mPEG,   
 Poly(vinyl alcohol) (PVA), 87-90% hydrolysed,  Mw 30,000-70,000, batch 
number 094K0104, chemical grade (Sigma Aldrich Inc., USA) 
 Sodium azide, (NaN3) batch number: 1001010, analytical grade (BDH 
Chemicals Pty Ltd., Kilsyth, Victoria) 
 Sodium chloride (NaCl),  batch number: 55914, analytical grade (Scharlau 
Chemie, Spain) 
 Sodium dihydrogen orthophosphate (NaH2PO4.H2O) ‘AnalaR’, analytical 
grade (Merck Pty.Ltd, Victoria) 
 Triamcinolone acetonide (TA) micronised, batch number: 
2196NMO0100421, chemical grade (Farmabios, Italy) 
 Water (deionised) - passed through a milli ‘Q’ apparatus with an initial 
specifc conductivity of 18 MΩ cm at 25˚C ( Millipore Corporation , Bedford, 
MASS, USA) 
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 All other chemicals were of analytical reagent grade.  
 
2.1.2 Experimental materials for in vitro toxicity study 
 ARPE 19 cell line,   kindly donated by Adj. Assoc. Prof. Chooi-May Lai 
(Lions Eye Institute, Western Australia) 
 BALB/c 3T3 cell line (ATCC, USA) 
 Dimethyl sulfoxide (DMSO), analytical grade (Sigma-Aldrich Chemie, 
Germany) 
 Media for culturing ARPE 19: 
Dulbecco’s Modified Eagle’s Media (DMEM) : Ham’s F12 1:1 media 
(GIBCO, Invitrogen Co., USA) containing 10% fetal calf serum (JRH, 
Germany), 100 IU Penicillin-100 µg/ml Streptomycin (GIBCO, Invitrogen 
Co., USA), 
 Media for culturing BALB/c 3T3 cells:  
DMEM containing sodium pyruvate (GIBCO),  10% fetal calf serum (JRH, 
Germany), 100 IU Penicillin-100 µg/ml Streptomycin ( GIBCO, Invitrogen 
Co., USA ) and 2 mM Glutamax (GIBCO, Invitrogen Co., USA) 
 Methylene blue, analytical grade  (Sigma-Aldrich Chemie, Germany) 
 0.9% NaCl / saline solution for irrigation ( Baxter, Australia) 
 Trypsin-EDTA (GIBCO, Invitrogen Co., USA) 
 Triamcinolone acetonide (TA), micronised, (batch number: 
2196NMO0100421 (Farmabios, Italy) 
 
2.2 Instrumentation 
2.2.1 Instrumentation for TA-NPs formulation 
 Sonicator; Biosonik II (Bronwill Scientific, New York, USA), 
 Bath sonicator; Bransonic Ultrasonic cleaner 2510E-DTH (Branson 
Ultrasonic Corporation,    USA); 
 Centrifuge; Allegra™ 64R centrifuge (Beckman Coulter, Inc., USA); 
Eppendorf minispin AG 22331 (Eppendorf, Germany), 
 Field Emission Scanning Electrone Microscope (FESEM); Jeol JSM 6700F 
Japan,  with a sputter coater (JFC-1300, Auto Fine coater, Jeol, Tokyo, Japan)  
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 High Performance Liquid Chromatograph (HPLC) apparatus, consists of: 
 An Agilent 1100™ HPLC; an installation of a degasser (G1322A, serial # 
JP73022182), a quaternary pump (G1311A, serial # DE91610024), an 
automatic sampler (G1313A, serial # DE91612069), a diode array detector 
(G1315B, serial # DE01609022) and a ChemStation working station 
 An Econosil™ column, C18 10 µm, 250 x 4.6 mm (Alltech Associates Inc,  
PA, USA), as the column for a reverse-phase HPLC analysis; 
 NP sizer;  Zetasizer 3000HS, Malvern Instrument, UK, 
 Magnetic stirrer; Variomag telemodul 20P (Dr Hoss + Partner GmBH, 
Germany), 
 Oven (Memmert, Germany); 
 pH meter; Microprocessor pH/mV/ºC Meter, Model: 8417N, (Hanna 
Instruments,    Singapore), 
 UV-Vis spectrophotometer; diode array spectrophotometer 8452 A (Hewlett 
Packard, USA) and UV-Visible spectrophotometer 1201 (Shimadzu, Japan), 
 Vacuum rotary evaporator; Buchi Rotavapor R-200 (Buchi Labortechnik AG, 
Switzerland). 
 
2.2.2 Instrumentation for in vitro toxicity study 
 Aseptic hood; Email™ Air Handling Hood, Biological Safety Cabinet, Type: 
Class II 1800     RH, conforming to 2252 part2 1994, Model No. 1687, 
(WestingHouse, Australia), 
 CO2 incubator; Sanyo CO2 incubator, MCO-17AIC, (Sanyo Electric Co, Ltd, 
Japan), 
 Centrifuge; Eppendorf™ centrifuge 5417C (Hamburg, Germany), Beckman 
GS-6 centrifuge, Germany 
 Phase contrast microscope; Nikon phase contrast microscope, model TMS, 
Japan 
 Microplate reader; Microplate reader model 3550 (BioRad, USA)  
 Water bath, Thermoline™ water bath, Australia 
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2.3 Methods 
2.3.1 High Performance Liquid Chromatography (HPLC) 
assay validation for TA 
The TA HPLC method was adopted from a reported method 74 with some 
modification. An Econosil column, C18 10 µm, 250 x 4.6 mm (Alltech Associates 
Inc, PA, USA) was used as the stationary phase. The mobile phase consisted of a 
composition of acetonitrile (ACN) and 20mM phosphate buffer solution (pH 4.2) in 
the proportion of 50:50 v/v, filtered through a 0.45 µm membrane filter prior to use. 
The flow rate of 1.5 mL/min and the injection volume of 20µl were used. The assay 
validation was conducted with TA standards dissolved in two media: the 
ACN:mobile phase 1:1 v/v and phosphate buffer saline pH 7.4 containing 0.05% w/v 
sodium azide (PBS-NaN3). To obtain a maximum sensitivity, TA was measured at its 
wavelength of maximum absorption: 242 nm. The temperature of the system was 
maintained at 25ºC. The HPLC assay of TA was validated for linearity, precision, 
recovery (accuracy), sensitivity and selectivity. 
 
Linearity 
Linearity of the assay was determined in two types of media for TA loading and 
release study i.e. ACN:mobile phase 1:1 v/v and PBS-NaN3, respectively. The 
standard solutions were injected directly into the HPLC column under the conditions 
described in Section 2.3.1. The calibration curve was constructed for each type of 
medium by plotting peak areas against the concentration of TA standard solutions. 
 
TA in ACN:mobile phase 1:1 
Six standard solutions at concentrations of 1, 2, 5, 10, 30, and 40 µg/mL were 
prepared by diluting a 50 µg/mL of TA stock solution in ACN:mobile phase 1:1 v/v. 
 
TA in PBS-NaN3 pH 7.4 
A 50 µg/mL of TA stock solution in PBS-NaN3 was diluted to obtain standard 
solutions  ranging between 0.5 µg/mL and 25 µg/mL. Due to the TA solubility 
problem, the stock solution was prepared by dissolving 12.5 mg TA in 100 mL of 
ACN and making up to 500 mL with PBS-Na N3. 
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 Preparation of PBS-NaN3 solution 
The method of preparation for Sorensen buffer was adapted from the Pharmaceutical 
Codex (ref) to prepare 40 mM phosphate buffer saline solution (PBS) pH 7.4, with a 
replacement of the di-sodium hydrogen orthophosphate dihydrate (Na2HPO4.2H2O) 
with anhydrous di-sodium hydrogen orthophosphate (Na2HPO4) containing an 
equivalent amount of salt. The solution was prepared by dissolving 7.6 g of 
Na2HPO4, 2.1 g of sodium dihydrogen orthophosphate (NaH2PO4.2H2O), and 4.4 g 
of sodium chloride (NaCl) in 1000 mL of Milli ‘Q’water. Sodium azide, NaN3 
(0.05% w/v) was included as a preservative in the PBS solution.  
 
System precision 
Six replicate injections of two different concentrations of TA (low and high 
concentrations) were assessed for the precision of the assay. The study was 
conducted in two media: loading medium and release medium. The means and 
relative standard deviations (RSD) were calculated for each TA concentration. 
 
Recovery (accuracy) 
Six concentrations ranging between 2.5 µg/mL and 40 µg/mL were analysed in the 
presence of a known volume of 20 µg/mL of empty PLGA, mPEG-PLGA (4.8%) 
and PDLLA NPs by the same method used for TA loading determination. The final 
solutions were filtered with a 0.2 µm syringe filter (GHP Acrodisc® 13, Pall 
Corporation, USA) prior to injection into the HPLC column. The recovery was 
calculated by comparing the actual TA concentration detected with the initial 
concentration. 
 
Sensitivity 
Blank solvents were injected six times consecutively into the HPLC column and the 
standard deviation of average noise levels in the expected retention time were 
determined. For the TA loading determination assay, blank solvent was defined as 
the loading media after being filtered from blank NPs, while in the release study, 
blank solvent was the PBS-NaN3. The theoretical LOD and LOQ were then 
calculated by the following formulae:  
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3
curvencalibratioofionconcentratversusheightofslope
levelsnoiseofdeviationndardtasLOD  (Eq.1) 
10
curvencalibratioofionconcentratversusheightofslope
levelsnoiseofdeviationndardtasLOQ  (Eq.2) 
 
Selectivity 
The peak purity of TA in two different media (ACN:mobile phase 1:1 and PBS-
NaN3) containing TA and degradation products were analysed to determine the 
selectivity of the assay. The interference of the media was also investigated. The 
purity factor should be within the calculated threshold limit. 
 
2.3.2 Preparation of  TA-NPs 
Solvent diffusion method 
The solvent diffusion method in this study was developed based on the method 
reported by Murakami48. 
 
Polymeric organic phase preparation 
To prepare the polymeric organic phase, 0.4 g of polymer was dissolved in 20 mL 
acetone. The solution was then mixed well and served as the organic phase. 
 
Aqueous phase preparation 
Polyvinyl alcohol (PVA) with concentration of 0.6% (w/v) was used as the aqueous 
phase as well as the stabilizer solution. To prepare the PVA solution, 0.6 g of PVA 
was sprinkled onto 100 mL water and stirred overnight. The PVA solution was 
further filtered by a 0.2 µm syringe filter (GHP Acrodisc® 13, Pall Corporation, 
USA) to obtain a particle-free-solution. 
 
Preparation of TA-NPs by solvent diffusion 
Polymeric organic phase (20 ml) containing 80 mg of TA was added drop-by-drop 
into 60 mL of 0.6% PVA solution and constantly stirred at a speed of 300 rpm, at 
room temperature, for 4 hours to evaporate the acetone. The NP suspension was left 
on the bench for 30 minutes prior to purification. These procedures were repeated for 
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each type of polymer.  The empty NPs were prepared with the same method without 
the drug. 
 
Emulsification solvent evaporation method 
In this method, 0.4 g of polymer was dissolved in dichloromethane (DCM). The 
solution was mixed well and prepared as the organic phase. The same stabilizer 
solution as per section 2.3.2 was also used in the emulsification-solvent evaporation.  
 
Preparation of TA-NPs by solvent evaporation 
Polymeric organic phase (20 mL) containing 80 mg of TA, and 40 mL of 0.6% PVA 
solution were sonicated using the Biosonic® (Bronwill Scientific, USA) for 2 
minutes. The emulsion was then mixed with 20 mL of 0.6% PVA and continuously 
stirred for 10 minutes. The remaining DCM was removed by a rotary evaporator. The 
NP suspension was left on the bench for 30 minutes prior to purification. This 
procedures were repeated for each type of polymer. The empty NPs were prepared 
with the same method without the drug. 
 
2.3.3 NPs purification 
After evaporating the organic solvents, the NP suspension was centrifuged at 12,000 
rpm for 20 minutes using an Allegra 64R centrifuge (Beckman Coulter, Inc., CA, 
USA). The supernatant was collected and used to analyse the amount of PVA 
removed from the NP suspension. The determination of PVA content was described 
below. The settled NPs were then dispersed in 10 mL of deionised water.  
 
Determination of PVA content 
A colorimetric method, reported by Dalwadi et al. 62, was adopted to determine the 
PVA content in the supernatant obtained during the purification of NPs.  
 
To quantify the PVA in the nanoparticulate system, a calibration curve of absorbance 
versus PVA concentration was established. Standard solutions of PVA ranging     
from 18.9 µg/mL to 66.15 µg/mL were prepared from 2 mg/mL of the PVA stock 
solution. A volume of 5 mL of water was added into a known volume of standard 
solution, followed by the additions of 3 mL of 4% w/v boric acid and 0.6 mL of 
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0.1M iodine solution. The mixture was then made up to 10 mL with water accurately 
and kept in the dark for 5 minutes to optimize the formation of the complex. The 
PVA-iodine absorbance was measured using a UV-visible spectrophotometer 1201 
(Shimadzu, Japan) at 690 nm.  
 
Prior to PVA determinination, both supernatant obtained after NP centrifugation and 
PVA solution used to prepare NPs were diluted five times. To prepare the sample, 5 
mL of water was added to 0.1 mL of diluted supernatant (and PVA solution), 
followed by the additions of 3 mL of 4% boric acid and 0.1M of iodine solution. 
After it was made up to 10 mL with water, the mixture was kept in the dark for 5 
minutes. The absorbance was measured at 690 nm and the PVA concentration was 
quantified using a calibration curve prepared above. The PVA concentration was 
used to determine the PVA amount in the total volume of supernatant, which was 
equivalent to the amount of PVA removed from the nanoparticulate system. The 
percentage of PVA removal was calculated based on this equation: 
100(%) 
phaseaquoeusinPVAofamount
tnernataupstheinPVAofamountremovedPVA   (Eq.3) 
 
2.3.4 NP characterization 
Empty NPs and TA-NPs of each polymer were characterized in terms of morphology 
and size of NPs, zeta potential, yield, loading value, and entrapment efficiency. 
 
Morphology and size of NPs 
Morphology of the NPs was investigated using field emission scanning electron 
microscopy (FESEM). Briefly, the dried NPs were attached to the metallic studs with 
double sided carbon tapes and coated with gold by a sputter coater (JFC-1300, Auto 
Fine coater, Jeol, Tokyo, Japan) for 40 seconds with a 40 mA current intensity, prior 
to observation using FESEM (Jeol JSM 6700F, Japan). 
 
The size of the NPs in diluted samples were measured using a Zetasizer 3000HS 
(Malvern Instrument Pty. Ltd., Worcestershire, UK) based on a dynamic light 
scattering (DLS) principle,. The hydrodynamic diameter, which is represented as Z 
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average mean size, was determined at 25º C with a detection angle of 90º. The 
triplicate measurements were performed at 25ºC. 
 
Zeta potential 
The surface charge of the NPs, expressed as zeta potential, was also determined by 
the Zetasizer™, with a zeta mode based on the laser droppler anemometry principle. 
The measurements were also performed three times with diluted samples at 25ºC.   
 
Yield determination 
A known volume of NP suspension was added to a pre-weighed glass container and 
placed into an oven at 70ºC until the dried NPs reached constant weight (evaporation 
of  solvent complete). As a control, the same volume of water was also treated under 
the same condition. The yield of NPs was then determined by the following 
formulae: 
Yield of blank NPs (YNPs): 
100(%) 
polymerofweight
lesnanoparticdriedofweightYNPs     (Eq.4) 
 
 
Yield of TA-NPs (YTA-NPs): 
100
)(
(%)  drugpolymerofweight
lesnanoparticdriedofweightY NPsTA     (Eq.5) 
 
Determination of drug loading and entrapment efficiency 
A known volume of NP suspension was dissolved in 100 mL ACN to extract the 
drug from the NPs. The solution was then diluted 1:2 with the mobile phase, to 
precipitate the polymer. The precipitated polymer was removed by filtration with a 
0.2 µm syringe filter (GHP Acrodisc® 13, Pall Corporation, USA) prior to injection 
onto the HPLC column. For analysis of TA concentration, drug loading was 
calculated based on the following formula:  
100(%) 
obtainedlesnanoparticdriedofweight
loadeddrugofamountloadingDrug  (Eq.6) 
Whereas the entrapment efficiency was determined by this formula: 
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100(%) 
addeddruginitialofamount
loadeddrugofamountefficiencyEntrapment   (Eq.7) 
 
2.3.5 Turbidity assay 
Ten mL of 4 mg/mL TA in acetone was added into 30 mL of 0.6 % PVA and stirred. 
The samples were taken at time zero (t=0 min), t=2 minutes and at every 5 minutes 
thereafter and the mixture was continuously stirred. The absorbances of the samples 
were then determined using a diode array spectrophotometer 8452 A (Hewlett 
Packard, USA) at 400 nm. The sampling was carried out until the mixture reached 
equilibrium (the absorbance was relatively stable). The same method was used to 
study the precipitation of polymeric organic phase (20 mg/mL of PDLLA and mPEG 
PLGA) in acetone. The results compared the precipitation rate between the TA and 
polymers in the aqueous environment (0.6 % PVA solution). 
 
2.3.6 In vitro release assay of TA-NPs 
TA solubility study  
TA was added into release media until over saturated. The suspension were stirred at 
room temperature under controlled agitation. The samples were taken over 8 hours 
and 24 hours and filtered by a 0.2 µm syringe filter (GHP Acrodisc® 13, Pall 
Corporation, USA) prior to injection onto the HPLC column.  
 
Treatment of dialysis bag 
The dialysis bags were washed with running water for 3-4 hours to remove the 
glycerine. Those bags were then immersed in 0.3% w/v of sodium sulphide at 80º C 
for 1 minute to remove the sulphur. The sodium sulphide was removed by washing 
the bags with water at 60ºC for 2 minutes and acidifying it with 0.2 % v/v sulfuric 
acid. The bags were finally rinsed with hot water to remove the acid and stored in 
Milli ‘Q’ water at 4º C. The water was replaced daily to minimize the risk of 
microbial contamination. 
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In vitro release method 
The release study of TA-NPs was conducted using a dialysis bag diffusion technique. 
The experiment was performed in PBS-NaN3 at 37º C. The equipment was set up as 
shown in Figure 2.1. 
 
 
 
 
 
 
 
 
 
Figure 2.1: The dialysis bag diffusion equipment 
 
In brief, 10mL of TA-NPs of each polymer (containing 2.5mg of TA) was added to a 
4 cm of  dialysis bag, which was then sealed. The sealed dialysis bag was then 
soaked in 50mL of PBS-NaN3 and incubated at 37º C with constant shaking.  Forty 
mL of  samples were taken at 1, 2, 3, 4, 5, 6, 7, 8, 24, 72, and 96 hours, and replaced 
with an equal volume of fresh PBS-NaN3  to maintain the sink condition. The TA 
concentration in the samples was then analysed using the HPLC assay under the 
same conditions as in section 2.3.1. The release study was conducted in triplicates for 
each type of TA-NPs. 
 
Following controls were included in for the release study, 
Control 1: TA suspension (containing 2.5mg TA in 10mL water) prepared by a 
similar technique of solvent evaporation for TA-NPs excluding the polymer 
Control 2: TA suspension (containing 2.5mg TA in 10mL water) prepared by 
sonicating TA in water  for about 5 min 
 
2.3.7 Stability assay of TA 
The stability study of TA in the release medium (PBS-NaN3) was conducted under 
conditions with and without being loaded in the NPs.  
a glass container with lid
PBS-NaN3 as the release 
media a sealed dialysis bag containing TA or NPs suspension 
an orbital shaker 
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Stability assay of TA in aqueous environment  
The TA solutions with known concentrations were placed in 1.5 mL vials for 
sampling and kept under the experimental temperatures.  Samples were taken at 3, 6, 
9, 24, and 72 hours after initial incubation and determined by the HPLC assay as in 
section 2.3.1. The potency of TA was determined according to the following 
formulae: 
100(%) 
productsradationgdeandTAofareaspeaktotal
TAofareapeakTAofPotency                             
(Eq.8) 
The percentage of the degradation products was calculated by this formulae: 
100(%) 
productsradationegdandTAofareaspeaktotal
productsegradationdtheofareapeakproductnDegradatio     
                          (Eq.9)                                           
 
Stability of TA inside NPs 
The stability of TA inside NPs was assessed after conducting the 96-hour in vitro 
release study of TA-NPs. The unreleased TA was extracted by the same method as 
described in section 2.3.4. The potency and the degradation products were 
determined using Eq.8 and Eq.9, respectively. 
 
2.3.8 In vitro toxicity assay 
The assay was carried out with two different cell lines, which are BALB/c 3T3 
(fibroblasts) and ARPE 19 (retinal pigment epithelia) cell lines. The later was kindly 
donated by Adj. Assoc. Prof. Chooi May Lai (Lions Eye Institute), Western 
Australia. All related experiments were performed under aseptic conditions to avoid 
microbial contamination. 
 
Cell culture 
BALB/c 3T3 cells were maintained in Dulbecco’s Modified Eagle Media (DMEM) 
containing 2 mM of L Glutamax®, and supplemented by  10%  of fetal bovine serum 
(FBS), 100 U/mL of Penicillin, and 100 µg/mL of Streptomycin at 37ºC in 
humidified 5% CO2 atmosphere. The media is then known with an initial of D10.  
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The ARPE 19 cells were maintained in 1:1 mixture of DMEM and Ham’s F12 
containing 3 mM of glutamine 97, 98 with the same supplementation and under the 
same conditions as of BALB/c 3T3, the media then is known as DF12. 
 
Cell storage 
For long term storage, cells were stored in cryovials in liquid nitrogen (N2) storage. 
Prior to storage, 300 µl of FCS containing DMSO 9:1 (a freeze brew solution) was 
added into 300 µl the cell suspension in the cryovials as a cryoprotectant.  
 
Thawing the cells 
To bring up the cells from liquid nitrogen (N2) storage, the cells were first thawed 
rapidly at 37ºC and then 5 ml of the appropriate media was added. The cell 
suspension was then centrifuged at 1000 rpm for 5 minutes, the supernatant was 
removed and the cells were resuspended in 8 mL of fresh media. The cells were then 
placed into 80 cm3 flasks  and incubated  at 37º C. 
 
Subculturing (passaging) the cells 
Cell cultures were maintained until they reached approximately 80% confluence. The 
media was removed by aspiration, the cell monolayer was washed once with 
approximately 5 ml of saline and the cell harvested by addition of 1 ml of 0.2% of 
Trypsin-EDTA (Invitrogen, USA). Detachment of the cells was monitored by a 
phase contrast microscope. When the cells were detached, they were seeded into 
different flasks at an appropriate split ratio (1:3).   
 
Cell counts 
In order to standardize cell seeding into 96 well plates, cell counts were performed 
prior to seeding. Cells were harvested by Trypsin-EDTA as described above (in the 
section of subculturing the cells). Following detachment the cell suspension was 
centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded and cells were 
resuspended in 2 ml of fresh media.  To count cells, 20 µL of 0.4% Trypan blue was 
mixed with an equal volume of the cell suspension. The mixture was then added to 
the counting chamber and placed under the microscope. The cells were then counted 
on 25 squares with the following standard formula : 
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4102)25(/  squaresoncellstheofamountmLcellstheofAmount  (Eq.10) 
 
Cell optimization 
Cell optimization was conducted in order to determine the appropriate seeding 
density, which would provide an adequate response for the assay. The cell 
suspension (100 µL) was added in a 96-well plate in 3-4 different seeding densities 
(cells/well) and in three different plates, for three different examination times: 0, 24, 
and 48 hours. After 24 hour seeding at 37oC, the procedure of the MTT assay, as 
described in section of toxicity assay below, was performed for the 0 hour-plate. The 
same procedure was then repeated with the 24 and 48 hour- plates after 48 hours and 
72 hours seeding, respectively. The optimization graph of absorbance versus time for 
four seeding densities of the cells was constructed.  
 
Toxicity assay 
The MTT assay was performed on cells cultured in 96-well plates to determine the 
cell viability following 24 hour exposure to experimental samples.  Cells were 
inoculated into 96 well plates in 100 µL of appropriate media at seeding densities of 
15,000 cells/well for BALB/c 3T3 and 20,000 cells/well for ARPE 19. After cell 
inoculation, the cells were incubated for 24 hours prior to addition of experimental 
samples. After 24 hours, one plate was assayed to determine starting cell densities, 
this represent a measure of the cell population for each cell line at the time of 
samples addition (T0). The cells were treated by addition of freshly prepared 
samples: 
 TA in the media, in ten-fold concentrations ranging from 0.1 µg/mL to 1 
mg/mL(four wells per concentration),  
 TA-NP suspensions in media, of each polymer (PDLLA, PLGA, and 4.8% 
mPEG PLGA), containing various amount of TA as above, with various 
concentrations of NPs based on the loading value (four wells per certain 
amount of TA), 
 empty NP suspension in media, of each polymer, containing an equivalent 
amount of NPs as used in the TA-NP suspesions above (four wells per certain 
amount of NPs). 
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Cells without any treatment other than an addition of 100 µL  of media were used as 
controls. Following samples addition, the cells were incubated for an additional 24 
hours and the assay is terminated by adding 100  µL of MTT solution (1 mg/mL in 
appropriate media). The cells combined with an MTT solution were then incubated 
for 1 hour  at 37ºC. After the precipitation of purple fomazan, the MTT supernatant 
was removed and 100 µL of DMSO added to dissolve the purple formazan product.  
The absorbance of dissolved product was determined using a multiwell microplate 
reader 3550 (BioRad, USA) at a wavelength of 595 nm. The absorbance was 
corrected by reagents in the absence of cells and experimental samples. The toxicity 
assay was replicated three times. The toxicity of the samples is expressed as the 
percentage of cell viability in comparison to control cells. The control cells were 
assumed to be 100% viable. 
 
2.3.9 Statistical analysis 
All results of triplicate samples in each study are presented as mean ± SD, 
representing descriptive statistics. The statistical analysis for in vitro toxicity study 
was carried out using InStat® computer software. Unpaired t test was used to analyse 
the significance of the differences between TA and NPs. A significant difference was 
considered if the p value was less than 0.05 (p<0.05). 
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RESULTS AND DISCUSSION 
 
This study was conducted with two main objectives. The first was to develop 
polymeric NP formulations for delivery of TA, which would provide: low toxicity, 
sustained release properties and prolonged stability of TA. The second objective was 
to assess the toxicity of TA loaded NPs (TA NPs) compared with TA alone upon 
exposure to BALB/c 3T3 (fibroblasts) and ARPE 19 (human retinal pigment 
epithelial) cell lines. Since conventional TA administration is known causing 
potential side effects, it is expected that the NPs developed for TA administration can 
minimize potential side effects of TA by providing a controlled drug delivery to a 
target site. There have been concerns on the toxicity of NPs themselves, therefore, it 
is essential to study the toxicity of NP formulations with and without incorporation 
of TA. The ultimate aim of this study was to develop a safe and acceptable polymeric 
NP formulation for TA delivery that could have potential in ocular delivery.  
 
3.1 HPLC assay validation 
To determine the TA concentration, a HPLC assay developed by Gupta 74 was 
adopted with some modification. It was found that the original mobile phase 
containing ACN:20 mM phosphate buffer pH 4.2 in the proportion of 32:68 with a 
flow rate of 3 mL/min could not produce a distinct peak of TA. In order to achieve 
an optimum HPLC assay, a modification was made to reduce the wavelength to 242 
nm, change the proportion of mobile phase to ACN: 20 mM phosphate buffer pH 4.2 
50:50 and alter the flow rate to 1.5 mL/min. The internal standard was excluded 
since the assay recovery was satisfactory with external standards. 
 
The linearity of UV detector response was assessed for calibration curves in two 
different media: ACN:mobile phase 1:1 and PBS-NaN3. The former was the medium 
for the analysis of TA loading within NPs, and the latter was the release medium in 
the in vitro-TA-release study. Sodium azide (NaN3) was added as a preservative in 
the release media with the concentration of 0.05% to prevent microbial growth.  
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The range of TA concentration in the media of ACN:mobile phase 1:1 was from 1.03 
µg/mL to 41.20 µg/mL, while in the release media, the concentration ranged from 
0.264 µg/mL to 26.4 µg/mL. Correlation coefficient r2, an indication of the fitness of 
linear regression, was calculated for the calibration curve of area under the curve 
(AUC) against the TA concentration in both media. The detector’s response was 
found to be linear with r2 of 0.9999 and 1 for ACN:mobile phase 1:1 media and PBS-
NaN3, respectively. This suggests that the concentration of TA in the samples can be 
determined against the standard in the concentration range of calibration curve.  
Representative calibration curves are presented in Figure 3.1 and 3.2.  
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Figure 3.1: Standard curve for TA in ACN:mobile phase 1:1. TA was injected 
into HPLC in the range concentration of 1.03 µg/mL to 41.20 µg/mL, in 20µL 
injection volumes. Data is a representative of three independent calibration curves. r2 
was calculated by Microsoft Excel™ software. 
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Figure 3.2: Standard curve for TA in PBS-NaN3.  TA was injected into HPLC in 
the range concentration of 0.264 µg/mL to 26.4 µg/mL, in 20µL injection volumes. 
Data is a representative of three independent calibration curves. r2 was calculated by 
Microsoft Excel™ software. 
 
System precision for the HPLC assay is shown in Table 3.1. Six injections (20 µL 
volumes) were carried out at the concentration of 1.03 µg/mL and 30.90 µg/mL with 
ACN:mobile phase 1:1 as the medium. The relative standard deviation (RSD) of the 
injections was obtained below the nominal acceptable level of 2%. In the release 
medium, six injections of the concentration of 0.53 µg/mL and 5.27 µg/mL produced 
RSD of 0.53% and 0.08%, respectively, indicating that the injection of assay was 
precise for TA analysis. 
Table 3.1: System precision of the HPLC method for TA determination 
(a) 1.03 µg/mL of TA solution in ACN: mobile phase 1:1 
Injection numbers AUC (mAu*sec) 
1 26.78 
2 27.23 
3 27.78 
4 26.95 
5 27.15 
6 27.14 
Average 27.17 
RSD (%) 1.25 
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(b) 30.90 µg/mL of TA solution in ACN:mobile phase 1:1 
Injection numbers AUC (mAu*sec) 
1 788.93 
2 759.54 
3 759.19 
4 757.91 
5 764.13 
6 756.31 
Average 764.33 
RSD (%) 1.61 
 
(c) 0.53 µg/mL of TA in PBS-NaN3  
Injection numbers AUC (mAu*sec) 
1 13.08 
2 13.21 
3 13.11 
4 13.03 
5 13.20 
6 13.11 
Average 13.12 
RSD (%) 0.53 
 
(d) 5.27 µg/mL of TA in PBS-NaN3  
Injection numbers AUC (mAu*sec) 
1 129.85 
2 129.94 
3 130.09 
4 130.04 
5 130.13 
6 129.98 
Average 130.00 
RSD (%) 0.08 
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The accuracy of the HPLC assay was studied by examining the levels of recovery of 
TA in the presence of empty NPs made of three different polymers. The recovery of 
TA was investigated for determination of TA loading to assess the interference of the 
NP matrix in the assay. The results are presented in table 3.2.  
 
Table 3.2: Recovery of TA in the presence of empty NPs in mobile phase 
(a) PDLLA NPs as the empty NPs 
Initial concentration 
(µg/mL) 
Measured 
concentration (µg/mL) 
Recovery (%) 
2.56 2.70 105.20 
5.13 4.99 97.22 
10.26 9.93 96.81 
20.52 20.27 98.79 
30.78 30.25 98.28 
41.04 40.47 98.62 
Mean ± SD 99.15 ± 2.79 
 
Regression analysis 
Test Results 
Slope 0.9849 
Intercept -0.0069 
Correlation coefficient 0.9999 
95% CI slope 0.9738-0.9960 
95% CI Y-intercept -0.5187 to 0.5050 
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(b) PLGA NPs as the empty NPs 
Initial concentration 
(µg/mL) 
Measured 
concentration (µg/mL) 
Recovery (%) 
2.56 2.67 103.97 
5.13 5.07 98.85 
10.26 10.09 98.38 
20.52 20.15 98.20 
30.78 30.49 99.06 
41.04 40.91 99.68 
Mean ± SD 99.69 ± 1.97 
 
 
Regression analysis 
Test Results 
Slope 0.9941 
Intercept -0.00885 
Correlation coefficient 0.9999 
95% CI slope 0.9813-1.0070 
95% CI Y-intercept -0.6809 to 0.5036 
 
(c) mPEG PLGA as the empty NPs 
Initial concentration 
(µg/mL) 
Measured 
concentration (µg/mL) 
Recovery (%) 
2.56 2.69 104.89 
5.13 5.14 100.23 
10.26 9.97 97.20 
20.52 20.21 98.49 
30.78 30.55 99.24 
41.04 40.78 99.38 
Mean ± SD 99.91 ± 2.41 
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Regression analysis 
Test Results 
Slope 0.9921 
Intercept -0.0267 
Correlation coefficient 0.9999 
95% CI slope 0.9798 – 1.0045 
95% CI Y-intercept -0.5961 to 0.5427 
 
In the presence of empty PDLLA NPs, the 95% confident interval (CI) of the slope 
was 0.9738-0.9960, not including 1 (Table 3.2.a). It indicates that the TA was not 
totally recovered by the assay method in the presence of the PDLLA matrix. 
However, the average of recovery was in the value of  99.69 ± 1.97%, with a slope 
and the correlation coefficient of 0.9849 and 0.9999, respectively. The 95% CI of Y-
intercept goes through zero, therefore, this level of recovery was considered 
acceptable. Other tables, which show the recovery levels in the presence of empty 
PLGA NPs (Table 3.2 (b)) and empty 4.8% mPEG-PLGA NPs (Table 3.2 (c)), 
revealed 95% CI of slope including 1 and 95% CI of Y-intercepts going through 
zero. These data indicate that the assay is unbiased and produces a satisfactory 
recovery. 
 
The recovery of TA in the release media was not carried out since there was no 
extraction method prior to TA determination by HPLC in the release study. 
Moreover, the release study was conducted using the dialysis bags and the samples 
were taken from the media outside the dialysis bag. The molecular weight cut-off 
(MWCO) of the dialysis bag was about 12,400 Da, therefore it would allow TA to 
freely pass through, while the NPs, whose size is much larger than MWCO, would be 
likely to be retained inside the bag. 
 
In order to assess the sensitivity of the assay, the theoretical minimum LOD and 
minimum LOQ were determined both in the loading determination and in the release 
study.  The theoretical LOD and LOQ for loading determination, which includes the 
extraction process of three different types of NPs, were approximately 0.107 µg/mL 
and  0.336 µg/mL, respectively (Table 3.3). In the release study, the HPLC assay for 
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TA determination was theoretically able to detect  TA at levels above 0.053 µg/mL, 
and to provide accurate quantification of TA above 0.180 µg/mL. A sample of  LOD 
and LOQ  calculation is shown in appendix 1. 
Table 3.3: LOD/LOQ of the HPLC assay for TA determination 
 LOD (µg/mL) LOQ (µg/mL) 
Loading determination: 
- PDLLA NPs 
- PLGA NPs 
- mPEG PLGA NPs 
 
0.090 
0.094 
0.118 
 
0.299 
0.315 
0.394 
Release study: 0.053 0.180 
 
Selectivity in the HPLC assay development was assessed to determine that the peaks 
can be well-separated and the purity factor of the drug analysed is within the 
calculated threshold.  The typical HPLC chromatograms of TA and degradation 
products are illustrated in Figure 3.3 from (a) to (f).   
 
 
Figure 3.3: (a) Typical HPLC chromatogram of TA standard in ACN:mobile 
phase 1:1 
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Figure 3.3: (b) Typical HPLC chromatogram of extraction of empty NPs in 
ACN: mobile phase 1:1 as blank 
 
 
 
 
 
Figure 3.3: (c) Typical HPLC chromatogram of TA extraction from loaded NPs 
in ACN: mobile phase 1:1  
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Figure 3.3: (d) Typical HPLC chromatogram of TA standard in PBS-NaN3 
 
 
 
 
 
 
 
 
Figure 3.3: (e) Typical HPLC chromatogram of TA (peak 1) and  degradation 
product (peak 2) in PBS-NaN3 at 37°C over 24 hours 
 
 
 
 
2 
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Figure 3.3: (f) Typical HPLC chromatogram of PBS-NaN3 (release medium) 
 
The retention time of TA and its degradation product (which is speculated to be 6β-
hydroxyltriamcinolone72) were approximately 3.7 and 2.9 minutes respectively, 
showing that they were completely separated (Figure 33.(e)) In the release medium, 
the buffer substances and the sodium azide (NaN3, a preservative) eluted faster than 
TA (at 1.6 minutes), suggesting that those compounds did not interfere with the TA 
analysis. Traces of PVA, in the loading determination were not detectable at a UV 
wavelength of 242 nm. In addition, the purity factor of the TA peak calculated by the 
Chemstation software package was within the calculated thresholds, indicating that 
the peak of TA was free from interference (see appendix 2).  
 
3.2 Formulations of TA loaded NPs (TA-NPs) 
The main objective of the current study was to develop NP formulations for TA 
which provide low toxicity, sustained release properties and prolonged stability. This 
study involved investigation of three different types of polymer, i.e poly- (D.L. 
lactide) (PDLLA), poly-(D,L,lactide-co-glycolide) (PLGA) and methoxy-poly 
ethylene-glycol-poly(D,L,lactide-co-glycolide) (mPEG PLGA) containing 4.8% 
polyethyleneglycol (PEG), for preparation of NPs. The solvent diffusion method was 
initially chosen to produce NPs, considering that it can produce particles sized 
around 200 nm using non toxic solvents and the production can be conducted in mild 
conditions 47-50, 57.  
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In the solvent diffusion method, acetonic solution containing polymer (for empty 
NPs) and polymer plus TA (for TA loaded NPs) was added dropwise into the PVA 
solution under mild agitation. The mixture of those solutions appeared to be opaque, 
since the NPs rapidly precipitated.  
 
Table 3.4: Physical characteristics of empty NPs made by solvent diffusion 
method 
Properties PDLLA NPs PLGA NPs mPEG PLGA NPs
Particle size (nm) 284.93 ± 25.46 274.57 ± 5.09 212.77 ± 3.67 
Polydispersity index 0.09 ± 0.02 0.07 ± 0.01 0.04 ± 0.01 
Zeta Potential (mV) -28.20 ± 3.24 -33.70 ± 0.90 -35.17 ± 3.47 
Yield (%) 72.98 ±  8.71 84.38 ± 1.09 90.21 ± 1.91 
 
All particles produced by the solvent diffusion exhibited small size, around 250 nm, 
with negatively charged surfaces (Table 3.4). About 80% yield was achieved by the 
solvent diffusion technique for empty NPs. The properties varied with nature of the 
polymers. Since the solvent diffusion technique involves a rapid diffusion of acetone 
into water, this rate of diffusion would affect the rate of formation and precipitation 
of NPs.  From the results, it can be seen that the increased hydrophobicity of the 
polymer correlated with increased size.  
 
Based on the properties obtained from empty NPs, incorporation of TA into NPs was 
carried out. Initially, it was found that the level of TA incorporated into PDLLA NPs 
appeared to be good (Table 3.5).  
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Table 3.5: Results of initial study of TA incorporation into PDLLA NPs by 
solvent diffusion 
Batch No. Particle 
size (nm) 
Polydispersity
index 
Yield (%) Loading 
(%) 
Entrapment 
efficiency 
(%) 
6 240.8 0.01 72.03 31.41 67.90 
9 242.9 0.10 69.89 31.87 66.69 
17 219.9 0.06 75.28 14.5 65.80 
 
However, further investigation, conducted on the morphological characteristics of 
TA-PDLLA NPs, revealed that the NP suspension contained a mixture of TA-
PDLLA NPs and TA crystals. Figure 3.4 shows a scanning electrone microscopy 
(SEM) image of TA crystals found in the initial TA-PDLLA NPs sample.  We 
hypothesised that, although the polymer was able to form NPs immediately after 
being introduced to the PVA solution, TA was less entrapped in NPs during diffusion 
process, instead, most of TA precipitated in the PVA solution. This led to artificially 
high entrapment efficiency. To test this hypothesis, the next study was carried out. 
 
 
Figure 3.4: SEM of TA crystal in TA-PDLLA NPs.  
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Turbidity study 
To assess the order of precipitation between polymer and TA during formation of 
NPs in the solvent diffusion method, the turbidity study was conducted on two types 
of polymer: PDLLA and mPEG-PLGA. The former has the most hydrophobic 
characteristics whereas the later is the most hydrophilic polymer used in this study.  
In this turbidity study, the experiment was designed similarly as for preparing the 
NPs, except that the polymer-acetonic solution and TA-acetonic solution were 
poured individually into PVA solution. The precipitation (turbidity of solution) was 
determined at a UV wavelength of 400 nm. A mixture of acetone and PVA solution 
was used as blank. Figure 3.5 shows that the polymers precipitated immediately after 
being introduced to the PVA solution, while TA took about five minutes to be 
precipitated. This suggests that only a small amount of TA might be incorporated 
into NPs due to the rapid precipitation of the polymers.   
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Figure 3.5: Turbidity profile of TA and polymers. The absorbance was evaluated 
at wavelength of 400 nm in certain time points during solvent diffusion process. The 
mixture of 0.6% PVA solution and acetone was used to correct the background    
 
Modification of solvent diffusion method 
The solvent diffusion method was modified to separate the TA crystals from TA-NPs 
produced by solvent diffusion process. In order to separate NPs from TA crystals, the 
NP suspension containing TA crystals was left on the bench for about 30 minutes. 
The settled TA crystals were then separated from NP suspension prior to 
centrifugation of NP suspension at 12,000 rpm for 20 minutes. The physical 
characteristics of the NPs prepared by this optimised method are shown in Table 3.6. 
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Table 3.6: Properties of TA-loaded- NPs made by the optimised solvent 
diffusion method 
Properties TA-PDLLA NPs TA-PLGA NPs TA-mPEG 
PLGA NPs 
Particle size (nm) 256.7 ± 2.54 279.0 ± 19 233.63 ± 4.29 
Polydispersity index 0.057 ± 0.005 0.040 ± 0.020 0.090 ± 0.001 
Zeta Potential (mV) -30.53 ± 0.95 -33.06 ± 2.31 -30.05 ± 1.20 
Yield (%) 50.08 ± 4.27 60.04 ± 5.89 82.73 ± 1.90 
Loading (%) 1.57 ± 0.73 2.47 ± 0.34 2.94 ± 0.25 
Entrapment efficiency (%) 4.23 ± 1.79 7.91 ± 1.07 12.3 ± 0.87 
 
In terms of the characterisation of NPs, the smallest particles were obtained in TA-
mPEG PLGA NPs (around 230 nm), followed by TA-PLGA NPs and TA-PDLLA 
NPs (around 260 nm). The small size of TA-mPEG PLGA was due to the PEG 
content on mPEG PLGA. Beletsi et al 99 and Avgoustakis et al 54 suggest that PEG 
has the ability to mediate the association of polymer molecules during the formation 
of NPs. In terms of entrapment efficiency and loading value, we revealed that the 
entrapment efficiency and the load value of TA-NPs, especially TA-PDLLA NPs, 
were extremely low, around 1% and 5% respectively. However, the result of TA-
PDLLA NPs particle size is in agreement with other study conducted by Liu et al 50. 
They demonstrated that the particle size of PLA NPs of 231.5 ± 32.1 nm was 
obtained with the same polymer concentration (2%). Berton et al 100, in their study of 
incorporating oligonucleotide complex (a hydrophobic drug model) into PDLLA, 
revealed that the actual loading of only 2.91% w/w could be obtained for a 
theoretical loading of 10%. The failure to entrap the drug was possibly due to the 
rapid diffusion of the acetone to outer phase. As the mechanism of this method 
involves diffusion of solvent, 48, 58, 101, a rapid diffusion may cause the polymer to 
solidify rapidly.  Due to the poor solubility of the hydrophobic polymers in aqueous 
stabiliser solution, polymer aggregation may occur at the same time with NP 
formation, resulting in a low level of yield of NPs. Leo et al 102 also suggested that a 
substantial decrease of yield with the increased of drug loading may be due to the 
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rapid diffusion of the drug to external aqueous phase during NP solidification. This 
suggestion was correlated to the study conducted by Govender et al 20 
 
Since the loading and entrapment efficiency of NPs prepared by the solvent diffusion 
method were undesirable, the second technique of NP preparation was studied. 
Emulsification-solvent evaporation, also known as solvent evaporation, is the most 
common method for preparing polymeric nano- and microparticles. In this method, 
droplet formation, droplet stabilisation and solidification of NPs after solvent 
evaporation play an important role in controlling the size of NPs 30. The formation of 
NPs is achieved by evaporating the organic solvent which is immiscible with water. 
Although it involves organic solvent which is considered potentially toxic, the level 
of organic solvent can be reduced with a proper evaporation method.  
 
DCM containing polymer (for empty NPs) and polymer plus TA (for TA-NPs) were 
emulsified in the PVA solution by sonication. The emulsion was then solidified 
under mild agitation prior to DCM evaporation by a rotary evaporator (Buchi, 
Germany). In the study of praziquantel loaded NPs, Mainardes and            
Evangelista 56 demonstrated that evaporation of the organic solvent using a rotary 
evaporator, with reduced pressure, offered smaller particles and a more efficient 
process with regards to drug entrapment, compared to the same process using a 
magnetic stirrer.  
Table 3.7: Physical characteristics of empty NPs made by emulsification-solvent 
evaporation method 
Properties PDLLA NPs PLGA NPs mPEG PLGA NPs
Particle size (nm) 338.57 ± 17.75 292.38 ± 3.45 274.29 ± 11.88 
Polydispersity index 0.11 ± 0.02 0.08 ± 0.01 0.060 ±0.005 
Zeta Potential (mV) -36.2 ± 1.60 -34.24 ± 1.27 -34.80 ± 0.82 
Yield (%) 89.42  ± 3.00 91.03 ± 5.23 88.11 ± 3.95 
 
The particle size of three types of NPs, which varied with the type of polymer, was 
found to be larger than the formulations with the solvent diffusion method due to 
slow evaporation of DCM (Table 3.7). The surface charges were found to be highly 
negative, indicating that the NPs were in a stable suspension. Regarding the yield, 
this technique produced more NPs compared to the solvent diffusion method.  
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Incorporating of TA into NPs was also carried out by solvent evaporation method. 
As expected, the particle size of TA-NPs was larger than that of empty NPs.  
Table 3.8: Properties of TA-loaded- NPs made by emulsification-solvent 
evaporation method 
Properties TA-PDLLA 
NPs 
TA-PLGA 
NPs 
TA-mPEG PLGA 
NPs 
Particle size (nm) 360.35 ± 1.91 326.85 ± 0.35 291.35 ± 4.03 
Polydispersity index 0.03 ± 0.02 0.030 ± 0.005 0.06 ± 0.03 
Zeta Potential (mV) -33.25 ± 8.56 -32.85 ± 6.43 -32.15 ± 2.76 
Yield (%) 79.39 ± 1.86 92.30 ± 2.06 87.61 ± 4.05 
Loading (%) 6.09 ± 0.85 12.00 ± 0.43 12.69 ± 0.85 
Entrapment efficiency (%) 29.57 ± 4.55 67.26 ± 4.11 63.06 ± 1.69 
 
 55
 
 
(a) 
0
20
40
60
80
100
Yield Loading Entrapment Efficiency
V
al
ue
 (%
)
TA-PDLLA NPs TA-PLGA NPs TA-mPEG PLGA NPs
 
(b) 
0
20
40
60
80
100
Yield Loading Entrapment
efficiency
V
al
ue
 (%
)
TA-PDLLA NPs TA-PLGA NPs TA-mPEG PLGA NPs
 
Figure 3.6: Comparison of yield, loading and entrapment efficiency values of 
three types of NPs. The NPs were made by the optimised solvent diffusion method 
(a) and solvent evaporation (b). The data is presented as mean ± SD (n=3). The error 
bars represent standard deviation of triplicate samples.   
 
Although the particle size and zeta potential showed expected values, loading and 
entrapment efficiency of TA-NPs made by solvent diffusion method were out of 
expectation (Figure 3.6 (a)). The low drug entrapment efficiency and loading could 
be due to the rapid diffusion of acetone into water, which led to the rapid 
precipitation of polymers. Based on the obtained data, we can conclude that, when 
NPs are prepared by solvent diffusion method, a small quantity of the drug could be 
encapsulated leading to low entrapment efficiency. In other words, the solvent 
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diffusion method is only capable for producing NPs with a low entrapment 
efficiency.   
 
In solvent evaporation method, TA-NPs with substantial higher loading values could 
be achieved (Figure 3.6 (b)). The high drug loading and entrapment efficiency were 
achieved in both TA-mPEG PLGA NPs and TA-PLGA NPs. The yield of NPs was 
greatest with TA-PLGA NPs and TA-mPEG PLGA, but less with TA-PDLLA NPs.  
The incomplete recovery for TA-mPEG PLGA was due to the limitation of 
purification, in which the speed of centrifugation was not high enough to settle the 
mPEG PLGA NPs, resulting in loss of NPs during supernatant (PVA) removal. The 
purification of NPs will be further discussed as per section 3.5. Low levels of 
loading, entrapment efficiency as well as the yield of TA-PDLLA NPs were due to 
the formation of TA crystals, microparticles and polymer aggregation, which were 
separated from NPs prior to centrifugation. 
 
The morphological characteristics of TA-NPs prepared by solvent evaporation were 
examined. Field emission scanning electron microscopy (FESEM) was used to 
capture images of TA-NPs. 
 (a) 
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(b) 
 
 
(c) 
 
 
 
Figure 3.7: FESEM image of TA-NPs. TA-NPs were prepared by solvent 
evaporation method. (a) TA-PDLLA NPs, (b) TA-PLGA NPs, (c) TA-mPEG PLGA 
NPs. Images were taken at 15,000 magnification. 
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The morphological characteristics of TA-PDLLA NPs, TA-PLGA NPs and TA-
mPEG PLGA made by emulsification solvent evaporation show that the NPs were 
spherical, with size less than 500 nm (Figure 3.7). No free TA crystals mixed with 
the NPs were detected. The connection that appeared in between NPs was maybe 
caused by the drying process or the presence of PVA residue on the surface of NPs. 
The size of the TA-PDLLA NPs appeared to be heterogeneous. In addition, TA-
mPEG PLGA appeared to be slightly smaller than the other two types of NPs. 
 
Those findings are correlated with particle size measurement by Zetasizer 3000HS 
(Malvern Instrument Pty. Ltd., Worcestershire, UK) which was based on dynamic 
light scattering. However, since the samples measured by Zetasizer™ was in a 
suspension, indicating that the NPs were fully hydrated, the particle size appeared to 
be larger than the FESEM samples, which have to be prepared in dry conditions. Due 
to time limitation, the size measurement on FESEM was only conducted on TA-
mPEG PLGA NPs made by solvent evaporation method (appendix 6). 
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Figure 3.8: TA-NPs characterisation. The column chart illustrates the comparison 
of yield, loading and entrapment efficiency obtained in TA-NPs made by solvent 
diffusion and solvent evaporation methods (a) TA-PDLLA NPs, (b) TA-PLGA NPs, 
(c) TA-mPEG PLGA NPs. Data is presented as mean ± SD (n=3).  
 
It is evident that in general, the solvent diffusion method can reduce the size to 
approximately 200 nm even less 47, 49, 50, 103. In the solvent diffusion method, the 
particle size of TA-PDLLA NPs was 256.7 ± 2.5 nm, whereas in the solvent 
evaporation the TA-PDLLA NPs sized around 360.4 ± 1.9 nm. The large particles 
(>200 nm) formed was possibly due to the combination of hydrophobicity of 
polymer and a relatively high polymer concentration. Zeta potentials of 
approximately -30 mV were found in both method, indicating that the NPs were 
well-dispersed and the suspension was stable. Solvent diffusion method produced a 
low yield value with TA-PDLLA NPs (Figure 3.8). This was due to the formation of 
aggregates and microparticles during the preparation process, which were settled and 
removed prior to purification. The entrapment efficiency was found to be very low 
with the NP preparation by the solvent diffusion method. This may be due to the 
rapid diffusion of organic solvent resulting in very rapid solidification of the polymer 
(PDLLA).  However, solvent evaporation can produce TA-PDLLA NPs with 
relatively higher entrapment efficiency.  
The similar patterns, which show that solvent evaporation was superior than solvent 
diffusion, were also shown in TA-PLGA NPs and TA-mPEG PLGA NPs. 
 
To determine the distribution of TA on the preparation of NPs, a mass balance study 
was conducted for all types of NPs (Table 3.9). The proportion of TA in the 
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supernatant was similar in all types of NPs, indicating that the quantity of TA in 
supernatant was controlled by the solubility of TA. Correlating with the result on 
entrapment efficiency, it was found that the greatest amount of TA precipitated was 
in TA-PDLLA NPs due to the poor entrapment of NPs.  
 
Table 3.9: Distribution of TA inside NPs, in supernatant and precipitate  in 
emulsification-solvent evaporation method 
Type of NPs Distribution of TA (%) 
Inside NPs In supernatant Precipitate 
TA-PDLLA NPs 37.01 ± 0.59 4.30 ± 0.45 54.62 ± 0.20 
TA-PLGA NPs 78.52 ± 0.44 4.31 ± 0.21 12.91 ± 0.43 
TA- mPEG-PLGA NPs 80.85 ± 0.28 4.09 ± 0.40 14.26 ± 0.61 
 
 3.2.1 NP purification by high speed centrifugation 
Purification of the NPs was analysed to remove potentially toxic impurities, such as 
traces of organic solvents, aggregates, surfactants or stabilisers. Polyvinyl alcohol 
(PVA) should be removed from the system in the preparation of NPs, since it is 
considered to be undesirable. Although PVA is reported as an effective stabiliser, 
which can assist to produce NPs with reduced size and high entrapment        
efficiency 36, 104, it is also reported by other investigator that PVA is a suspected 
potential carcinogen 105 .  
 
Various methods can be conducted to purify the NPs such as tangential flow 
filtration, diafiltration centrifugal devices (DCD) and high speed             
centrifugation 62. High speed centrifugation was selected as the method of 
purification for this study since it offered a simple and effective way to remove PVA. 
This method was carried out by centrifuging the NP suspensions at 12,000 rpm for 
20 minutes at room temperature followed by decanting the PVA-containing-
supernatant. 
   
We adopted the method reported by Dalwadi et al 62 to determine the level of PVA in 
the system before and after purification, in order to analyse the efficiency of removal. 
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The method is based on the complexation of two adjacent hydroxyl groups of PVA 
and an iodine molecule, in the presence of boric acid. The green coloured complex 
produces an intense absorbance band in the visible spectrum region at a wavelength 
of 690 nm. Figure 3.9 shows a representative of a calibration curve which was used 
to detect and quantify the amount of PVA remaining in the supernatant. A regression 
coefficient (r2) of 0.9964 was obtained, indicating that the absorbance was found to 
be linear with the concentrations of PVA, ranging from 19 to 67 µg/mL. A blank of 
the reagents excluding the PVA was used as zero concentration of PVA. 
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Figure 3.9: A representative of calibration curve of PVA determination. The 
curve was plotted on absorbance at 690 nm against PVA concentration in the range 
concentration of 19 to 67 µg/mL.  
 
Although high speed centrifugation offers satisfactory results in removing the PVA 
(Table 3.10), PVA still could not be 100% removed from the system. This finding is 
corresponding with the study reported by Murakami et al 48, 106 which revealed that 
small amount of PVA appeared to be attached on the surface of NPs as a result of 
hydrophobic bonding.    
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Table 3.10 : PVA removal on purification of NPs by high speed centrifugation 
Type of NPs PVA removed (%) 
Solvent diffusion method Solvent evaporation method 
TA-PDLLA NPs 94.28 ± 0.97 95.63 ± 0.37 
TA-PLGA NPs 96.62 ± 0.20 96.61 ± 1.83 
TA-mPEG PLGA NPs 96.66 ± 0.62 95.51 ± 2.03 
 
Effect of purification on particle size 
It is imperative to ensure that the method of purification does not affect the physical 
characteristics of NPs. To investigate the effect of purification on particle size, the 
particle size of the NPs before and after purification was analysed (Table 3.11).  
Table 3.11: Particle size of the NPs before and after purification 
Type of NPs Before purification After purification 
Particle size 
(nm) 
Polydispersity 
index 
Particle size 
(nm) 
Polydispersity 
index 
PDLLA NPs 307.87 ± 4.28 0.10 ± 0.02 324.77 ± 1.44 0.12 ± 0.02 
PLGA NPs 333.63 ± 1.33 0.07 ± 0.03 355.97 ± 2.12 0.06 ± 0.03 
mPEG-PLGA 
NPs 
230.80 ± 7.92 0.09 ± 0.02 233.63 ± 4.29 0.03 ± 0.02 
 
A slight increase in particle size was found after purification, to the extent that there 
was no difference on particle size observed on mPEG-PLGA NPs. Polydispersity 
index of three different types of NPs appeared to be similar before and after 
purification. Therefore, the effect of high speed centrifugation is negligible, 
suggesting that high speed centrifugation is an effective purification methods for   
NPs. 
 
3.2.2 Release characteristics of TA-NPs 
To investigate the characteristics of TA-NPs in providing sustained release, an in 
vitro release study of the NPs was conducted by dialysis bag diffusion method 
designed as per section 2.3.6. Sodium azide (NaN3, 0.05%) was added as a 
preservative in the release medium.  
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TA solubility in the release media was investigated prior to the release study, to 
determine the maximum concentration for maintenance sink conditions in the 
system. The design of solubility study can be seen on section 2.3.6. In this solubility 
study it was found that the solubility of TA was 6.58 ± 1.20 µg/mL over 8 hours, and 
27.40 ± 0.40 µg/mL over 24 hours (appendix 7).  In the release study, since the 
medium (PBS-NaN3) was replaced with the fresh one every hour over 8 hours and 
every 24 hours over 96 hours (in sampling time), it can be sure that the sink 
condition was achieved and TA solubility issues did not contribute to the release of 
TA from NPs .  
 
To develop a control, two TA suspensions in water containing a known amount of   
TA in different particle size, were used to examine the release profiles of free TA.  
Due to the limitations of instrumentation, the controls were only designed in micro-
size. The first control was made by a similar solvent evaporation procedure so as to 
make the NPs, excluding the polymer and PVA. As can be predicted, this method 
produced a TA suspension with the microparticles sized around 5.34 ± 0.25 μm.  In 
an attempt to reduce the size, the second control was established by sonicating the 
TA suspension for 5 minutes at room temperature. The size was found to be smaller 
than the first control, i.e. 2.86 ± 0.62 μm. 
 
Although it was not possible to design a control group which has the same particle 
size as the NP samples without an excipient or a stabiliser, it can be seen that the 
release of TA was more rapid with the reduction of size (Figure 3.10). It was 
speculated that if we can design the control group with nano-sized particles, the 
release of TA would be much faster.  
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Figure 3.10: Release profile of TA control groups over 96 hours. Release study 
was conducted at 37°C using a dialysis-diffusion bag method in the PBS-NaN3 as 
the release media. TA control 1 was prepared by the same method of solvent 
evaporation for NPs (5.34 ± 0.25 μm). TA control 2 was prepared by sonicating TA 
in water for 5 minutes in the absence of stabiliser (2.86 ± 0.62 μm). Both control 
groups containing the same concentration of TA as in the NPs. Data is presented as 
mean ± SD (n=3).  
 
Nevertheless, because the system was not supported by any surfactants and, the 
particles of TA in the control groups aggregated over time, resulting in the smaller 
surface area, and hence the rate of release was reduced.  
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Figure 3.11: Release profile of TA-NPs over 96 hours. Release study was 
conducted at 37°C using a dialysis-diffusion bag method in the PBS-NaN3 as the 
release media, (a) TA-PDLLA NPs (b) TA-PLGA NPs (c) TA-mPEG PLGA. TA 
control 2 was prepared by sonicating TA in water for 5 minutes in the absence of 
stabiliser (2.86 ± 0.62 μm). Both control and NPs contain the same concentration of 
TA. Data is presented as mean ± SD (n=3). 
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Figure 3.12: Overall release profiles of TA from TA-NPs over 96 hours. Release 
study was conducted at 37°C using dialysis-diffusion bag method in the PBS-NaN3 
as the release media. TA control 2 was prepared by sonicating TA in water for 5 
minutes in the absence of stabiliser (2.86 ± 0.62 μm). Both control and NPs contain 
the same concentration of TA. Data is presented as mean ± SD (n=3).  
 
 
The release profiles of TA from TA-NPs were found to be biphasic (Figure 3.11 and  
3.12). An fast constant release was observed over initial 8 hours (up to 20%) at a rate 
slower than TA control, indicating that TA was entrapped inside NPs and was 
dissolved and diffused out of NP matrix. This was followed by a sustained release up 
to 96 hours due to lower concentration gradient. Less than 60% of TA released over 
96 hours from TA-PDLLA NPs, while TA-PLGA NPs released around 80% TA over 
96 hours. TA was released slightly faster from TA-mPEG PLGA NPs than TA-
PLGA NPs. Around 90% of TA was released from TA-mPEG PLGA NPs. Hans and 
Lowman 12 reported that large particles would exhibit longer sustained release than 
small ones. They also illustrated that in terms of loading, the higher the loading may 
cause an increase in release rate. In our study, the release characteristics were mainly 
due to the nature of the polymers. In comparison with the control, TA-NPs exhibited 
slower release with decreasing TA released over time. This indicates that all three 
types of NPs exhibited sustained release characteristics.  
 
 67
0
10
20
30
40
50
60
0 2 4 6 8
Time (h)
C
um
ul
at
iv
e a
m
ou
nt
 o
f T
A
 
re
le
as
ed
 (%
)
TA control 2 TA-PDLLA NPs
TA-PLGA NPs TA-mPEG PLGA NPs
 
Figure 3.13: Release profiles of TA from TA-NPs over 8 hours. Release study 
was conducted at 37°C using dialysis-diffusion bag method in the PBS-NaN3 as the 
release media. TA control 2 was prepared by sonicating TA in water for 5 minutes in 
the absence of stabiliser (2.86 ± 0.62 μm). Both control groups containing the same 
concentration of TA as in the NPs. Data is presented as mean ± SD (n=3).  
 
Release profiles of TA from TA NPs at initial 8 hours are presented in Figure 3.13.  
All three types of polymer show fast release at a constant rate up to 20% due to the 
dissolution and diffusion of TA which was entrapped inside NPs, to the media. 
Although all types of NPs show an initial fast release, the cumulative TA released 
was about half that of  the control.   
 
Table 3.12: Distribution of TA after release process over 96 hours 
Distribution TA proportion (%) 
TA-PDLLA 
NPs 
TA-PLGA 
NPs 
TA-mPEG 
PLGA NPs 
TA 
(control) 
TA released over 96 h 
(in the  release medium) 
59.74 80.93 91.13 100* 
Unreleased TA  
(in the NPs) 
37.85 17.46 9.17 - 
Total 97.59 98.39 100.3  
*released in 72 hours 
 
Table 3.12 shows the distribution of TA after release over 96 hours. The unreleased 
TA was determined by the same method used for drug loading determination (section 
2.3.4.4) which was extracting the TA by dissolving the NPs into ACN. From that 
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distribution, it can be concluded that only TA-PDLLA NPs exhibited true sustained 
release, probably due to the more rigid of NPs. 
 
In summary, the difference of physical characteristics between TA-NPs in both 
methods was due to the nature of polymer and the solvent system used in the 
methods. The solubility of the drug and polymer in organic phase plays an important 
role especially in determining the entrapment efficiency. In the solvent diffusion, TA 
appeared to be very soluble in acetone. This led most of TA to diffuse out together 
with the organic phase to the aqueous phase. Although both TA and polymer are 
hydrophobic, it appeared that the interaction between TA and polymers was 
overweighed by the TA solubility in acetone. In the preparation of TA-NPs using the 
solvent evaporation the DCM was used as the organic solvent. In general we 
revealed that the particle size of TA-NPs was larger than those prepared by the 
solvent diffusion method. This was due to the slow evaporation of DCM. We also 
revealed that TA-PDLLA NPs were the largest particle with the lowest entrapment 
efficiency, while TA-mPEG PLGA NPs were the smallest particle with the highest 
entrapment efficiency. The release characteristics show that TA-mPEG PLGA NPs 
exhibited the fastest release of TA while the slowest release was shown in TA-
PDLLA NPs. These results led to the speculation that although the amount of TA 
associated with PDLLA was low, association of TA with PDLLA appeared to be the 
strongest. PDLLA was likely to entrap TA thoroughly rather than other NPs. In the 
TA-mPEG PLGA NPs, the PEG presence on mPEG-PLGA enhanced the 
hydrophilicity of polymer, resulting in the relatively higher water uptake into NPs. 
This was probably the cause of the fastest release of TA.   
 
3.2.3 TA stability study 
One of  the NP advantageous features is that they can protect the drug from 
hazardous environment and from potentially premature degradation 18. To determine 
whether the NP formulations could enhance the stability of TA in the aqueous 
environment, an investigation of the stability of TA in the aqueous medium was 
carried out. In this study, the potency of TA in aqueous solutions was determined 
over 72 hours after storage at three different experimental temperatures: 4°C, 25°C, 
and 37°C.  The potency of TA was calculated as a percentage of the TA peak area 
 69
over the total area of peaks (peaks of TA and degradation products). To exclude the 
possibility that limited drug solubility could reduce drug potency, both potency and 
degradation product were determined in each sample. In addition, the stability of TA 
inside the NPs was also investigated. The data of stability study are shown in 
appendix 3 and 4. 
 
Stability of TA in the extraction medium of ACN: mobile phase 1:1  
TA stability in the extraction medium was analysed using the HPLC assay of TA 
described in section 2.3.1. The results show that TA degraded slightly faster at higher 
temperatures (Figure 3.14).  Although Gupta 74 reported that TA is likely to be 
unstable at pH above 5.5 in an aqueous medium, a slow process of the degradation 
was also observed in the aqueous medium with pH approximately 7.  
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Figure 3.14: Potency of TA over 72 hours. Samples with a known concentration of 
TA in water were kept under experimental temperatures of 4°C, 25°C, and 37°C for 
96 hours.   
 
Stability of TA in the release medium 
The stability of TA in the release medium was assessed at 4°C, 25°C, and 37°C using 
HPLC assay as per section 2.3.1. To investigate whether the stability of TA is 
affected by microbial activity, the study was conducted in the release media, with 
and without a preservative. Figure 3.15 presented the potency of TA in the phosphate 
buffer solution (PBS) pH 7.4 with and without a preservative. It was found that the 
change of potency of TA appeared to be insignificant affected by the inclusion of 
preservative in the release media over 72 hours. It may suggest that microbial 
activity does not influence the degradation process of TA. 
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In the release medium, TA was degraded the fastest at 37°C, as predicted. After 72 
hours storage at 37°C, the degradation was increased dramatically up to 43%. A 
substantial decomposition of TA was found at room temperature, with TA  potency  
reduced to 85% over 72 hours, while at 4°C the TA showed less than 10% 
degradation (6.4%).  
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Figure 3.15:  Potency of TA at 72 hours. Samples with a known concentration of 
TA in PBS  and PBS–Na azide (PBS-NaN3) were kept under experimental 
temperatures of 4°C, 25°C, and 37°C for 96 hours.   
 
TA stability inside NPs 
To determine whether the NP formulations are able to maintain the stability of TA, 
the TA stability inside NPs was investigated. The study was conducted after 
completing a 96 hour in vitro release study.  The TA was extracted from the NPs and 
analysed for its concentration as per section 2.3.4.4.  Since TA in the control groups 
was 100% released in 72 hours, the potency of TA in the control groups was 
calculated with regards to 72 hours release. It was shown by the chromatogram 
(Figure 3.16) that after 96 hour release study at 37°C, TA remained in nature form 
inside NPs and no degradation product was detected. However, the free TA in the 
control groups was degraded up to approximately 12% over 72 hours. The data 
obtained suggests that the stability of TA was maintained satisfactorily by the 
polymer matrix of the NPs.  
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Figure 3.16: A representative of HPLC chromatogram of TA extraction from 
NPs. The extraction was carried out after 96 hour release study in PBS-NaN3 at 
37°C. 
 
3.3 In vitro toxicity study of  TA-loaded NPs 
The issues of toxicity of NPs have been raised up recently, in accordance with the 
potential clinical application of NPs. To investigate the effect of either TA or TA-
NPs, an in vitro toxicity study was carried out upon two different cell culture models: 
BALB/c 3T3 (fibroblasts) and ARPE 19 cells (human retinal pigment epithelial). The 
MTT assay was selected to determine the cell viability since it is a simple yet 
accurate assay 65, and is widely used in studies investigating polymers 44 and NP 
toxicity107-109.  The MTT assay was well-established in this laboratory. Previous 
research in this laboratory has found that the MTT assay is the most efficient at 
demonstrating toxic effects on cell viability if the final absorbance of the untreated 
cultures is in the range of 0.7-1.2. 
 
3.3.1 Assay optimisation 
In order to effectively show adequate responses to toxic compounds, it was necessary 
at the first stage, to optimise the seeding density (number of cells per well) in the 96 
well plates assay.  The process to optimise the cell number per well is described as 
per section 2.3.8 using the MTT assay. BALB/c 3T3 cells were seeding with seeding 
density in the range of 5,000 – 20,000 cells/well at three different plates reflecting 
three different time points: 0, 24 and 48 hours (Figure 3.17). The optimum seeding 
density for BALB/c 3T3 was determined at 15,000 cells/well based on the linearity 
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of the response (absorbance) against time and final absorbance was in the range 0.7-
1.2. 
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Figure 3.17: Seeding density optimisation of BALB/c 3T3.  The cells were 
inoculated in D10 media in a range of seeding density and incubated at 37°C. The 
cell viability was assayed by MTT assay at each time point. Data shown is a 
representative of three independent studies. 
 
Seeding density optimisation for ARPE 19 was also conducted as per section 2.3.8, 
with the same aim as that of BALB/c 3T3 (Figure 3.18). A range of seeding density 
was initially designed from 5,000 to 20,000 cells/well. In contrast to BALB/c 3T3 
expression, ARPE 19 demonstrated low intensity of absorbance at the same 
incubation time. This may indicate that mitochondrial activity of ARPE 19 cells was 
not as active as BALB/c 3T3 
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Figure 3.18: Seeding density optimisation of ARPE 19 (1).  The cells were 
inoculated in DF12 media in seeding densities ranging from 5,000 to 20,000 
cells/well and incubated at 37°C. The cell viability was assayed by MTT assay at 
each time point. Data shown is a representative of three independent studies. 
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Figure 3.19: Seeding density optimisation of ARPE 19 (2).  The cells were 
inoculated in DF12 media in seeding densities ranging from 15,000 to 25,000 
cells/well and incubated at 37°C. The cell viability was assayed by MTT assay at 
each time point. Data shown is a representative of three independent studies. 
 
In order to investigate if higher seeding densities were required for ARPE 19, a 
second experiment was carried out with 15,000 to 25,000 cells/well over 24 hours. 
As there was little improvement in the assay parameter at higher cell numbers, 
20,000 cells/well was selected for ARPE 19 toxicity studies (Figure 3.19).   
 
Interference of the test compounds/preparations on the MTT assay should be 
minimised in order to establish a valid assay. To investigate the possibility of such  
interference, an MTT assay was carried out with and without cells. In the absence of 
cells, the absorbance of residual samples was much lower than those of the presence 
of cells (Table 3.13). This indicates that the interference due to preparations or drug 
was minimal.   
 Table 3.13: Absorbance of samples with and without cells at 585 nm 
Samples Absorbance 
With cells Without cells 
TA suspension (1 mg/mL) 0.673 ± 0.067 0.013 ± 0.002 
TA-PLGA NPs with equivalent 
concentration of TA  
0.754 ± 0.094 0.017 ± 0.005 
Empty PLGA NPs with equivalent 
amount of NPs as of TA-PLGA NPs 
0.865 ± 0.030 0.015 ± 0.04 
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3.3.2 BALB/c 3T3 cell viability assessment 
 
 
Figure 3.20: Image of BALB/c 3T3 cells. Image was taken with an aid of a phase 
contrast microscope at 33x magnification. The cells were inoculated in D10 media 
(80% confluence). 
BALB/c 3T3 is the most common cell culture models used in toxicity study. Its 
feature of non tumorigenicity makes this cell model appropriate to study the toxicity 
of drugs which are not intended as anticancer agents. In order to assess the toxicity of 
TA and TA-NPs upon BALB/c 3T3, the study was carried out by exposing the cells 
to either TA or TA NPs over 24 hours at 37°C. The assessment was designed as per 
section 2.3.8.7.  The range of TA concentration was designed from 0.1 µg/mL to 1 
mg/mL based upon previous TA toxicity study conducted on ARPE 19 cells 98. The 
TA-NPs were prepared to give an equivalent concentration of TA. Empty NPs were 
prepared to give an equal amount of NPs to TA-NPs. In addition to MTT assay, 
treated and untreated cell cultures were also observed by phase contrast microscopy.  
To investigate the condition of the cells after exposure, phase contrast microscopy 
was used. An image of cells exposed to TA revealed that an aggregation of TA 
crystals was occurred, which appeared to induced cell death or inhibition around the 
location, resulting in a clear space between the cells (Figure 3.21.(a)). Contrary to 
that, TA-NPs were not visually detected by microscopy (Figure 3.21 (b)). The clear 
spaces were also observed in the cells exposed to TA-NPs but not as much as in the 
cells exposed to TA. 
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Figure 3.21: Image of BALB/c 3T3 cells after being exposed to TA and TA-NPs. 
Phase contrast microscopy 33x. Cells were exposed to samples for 24 hours at 37°C. 
(a) Cells were exposed to TA at a concentration of 1 mg/mL (b) Cells were exposed 
to TA-NPs containing the same concentration of TA.   
 
TA crystals 
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Figure 3.22: Effect of TA and TA-NPs on BALB/c 3T3  cell viability. Cells were 
seeded at 15,000 cells/well in D10 media and exposed to TA (0.1 µg/mL to 1 
mg/mL) and TA-NPs with drug concentration equivalent to TA, for 24 hours. The 
different chart designs are used to assist in understanding the effects of samples on 
the BALB/c 3T3 cell viability. (a) Cell viability against type of samples (b) Cell 
viability against TA concentration (mg/mL). Data presented as mean ± SD (n=3).  
 
The toxicity studies on BALB/c 3T3 cell model demonstrated a dose dependent 
decrease in cell viability with the increasing sample concentration (Figure 3.22). 
Although at the TA concentration of 0.1mg/mL and 1 mg/mL the cell viability was 
dramatically decreased, there was little effect on concentrations from 0.1 µg/mL to 
0.01 mg/mL. This indicates that the cells were not susceptible to TA at the 
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concentration at and below 0.01 mg/mL. Similar results were observed after 
exposure to all types of NPs at the same concentration of TA (0.1 µg/mL to 0.01 
mg/mL).   
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Figure 3.23: Effect of TA (1 mg/mL) and TA-NPs on BALB/c 3T3  cell viability. 
Cells were seeded at 15,000 cells/well in D10 media and were exposed to 1 mg/mL 
of either TA or TA-NPs with drug concentration equivalent to TA for 24 hours. Cell 
viability was determined using MTT assay. Data represent mean ± SD (n=3). The 
significant difference was considered if p < 0.05. 
 
At TA concentration of 1 mg/mL, the differences on the cell viability after being 
exposed to TA NPs compared to TA control were statistically significant (Figure 
3.33) with a reduction of cell viability down to around 50%. Among three types of 
NPs, TA PLGA NPs appeared to be the most effective in protecting the cells from 
TA toxicity.  Although only around 70% of cells were viable after being exposed to 
TA-NPs, it demonstrates that the TA NPs show significantly less cell toxicity than 
TA in this cell model. 
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Figure 3.24: Effect of TA (0.1 mg/mL) and TA-NPs on BALB/c 3T3  cell 
viability. Cells were seeded at 15,000 cells/well in D10 media and exposed to 0.1 
mg/mL of either TA or TA-NPs with drug concentration equivalent to TA for 24 
hours. Cell viability was determined using MTT assay. Data represent mean ± SD 
(n=3). The significant difference was considered if p < 0.05. 
 
At TA concentration of 0.1 mg/mL, the difference is not statistically significant due 
to the high levels of standard deviation, resulting from the biological variability 
between triplicate experiments (Figure 3.34). 
 
The relative contribution of the NPs themselves to toxicity was also investigated 
(Figure 3.35). The cell viabilities under exposure to TA loaded NPs containing the 
highest concentration of TA (1 mg/mL) and empty NPs containing an equal amount 
of NPs as the TA loaded NPs were assessed. The result demonstrates that the 
difference was not statistically significant, indicating that NPs did not contribute to 
the TA toxicity on BALB/c 3T3 cell model . 
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Figure 3.25: Effect of empty NPs and TA-NPs on BALB/c 3T3  cell viability. 
Cells were seeded at 15,000 cells/well in D10 media and exposed to either TA-NPs 
with TA concentration of 1 mg/mL or empty NPs with an equivalent amount of NPs 
to TA-NPs, for 24 hours. Cell viability was determined using MTT assay. Data 
represent mean ± SD (n=3).  
 
3.3.3 ARPE 19 cell viability assessment 
 
 
Figure 3.26: Image of ARPE 19 cells. A phase contrast microscopy at 33x 
magnification. The cells were inoculated in DF12 media (80% confluence). 
 
Recently, TA has been extensively investigated in the treatment of retinal diseases 84-
86, 91. Since TA-NPs are potential carriers to treat retinal diseases, it was imperative to 
test TA-NPs toxicity against a more specific and relevant cell model. TA has been 
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investigated for toxicity using ARPE 19 cells 97, 98, 110, therefore the non malignant 
retinal epithelial cell-line, ARPE 19, was used for this purpose.  
 
To assess the toxicity of TA and TA-NPs, in vitro toxicity studies were also 
conducted by exposing ARPE 19 cell culture to TA and TA-NPs over 24 hours at 
37°C. The range of TA concentration was similar to those applied on BALB/c 3T3 
cell viability assessment based on the previous toxicity study of TA conducted by 
Yeung 98. 
(a) 
 
(b) 
 
 
Figure 3.27: Morphology of ARPE 19 cells after being exposed to TA and TA-
NPs. Phase contrast microscopy at 33x magnification. Cells were exposed to samples 
for 24 hours at 37°C. (a) Cells were exposed to TA at a concentration of 1 mg/mL (b) 
Cells were exposed to TA-NPs containing the same concentration of TA.   
 
TA crystals 
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Phase contrast microscopy was also used to observe the cells exposed to TA and TA-
NPs. An aggregation of TA crystal was observed on the cells exposed to TA, 
however, the cell morphology appeared to be the same after exposure (Figure 3.37 
(a)).  The TA NPs were not detected by phase contrast microscopy due to sub-micron 
size of the NPs (Figure 3.37 (b)). Due to time limitation, investigation on 
morphological alteration after exposure on the cells was not conducted.  
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Figure 3.28: Effect of TA and TA-NPs on ARPE 19 cell viability. Cells were 
seeded at 20,000 cells/well in DF12 media and exposed to TA (0.1 µg/mL to 1 
mg/mL) and TA-NPs with drug concentration equivalent to TA, for 24 hours. The 
different chart designs are used to assist in understanding the effects of samples on 
the BALB/c 3T3 cell viability. (a) Cell viability against type of samples (b) Cell 
viability against TA concentration (mg/mL). Data presented as mean (n=3) ± SD.  
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High toxicity of TA after 24 hour exposure to ARPE 19 was observed at the highest 
concentration (1 mg/mL) (Figure 3.38 (a)). It reduced the cell viability down to 60%.  
The differences in cell viability after 24 hour exposure to TA and TA-NPs, at the TA 
concentration of 1 mg/mL, were statistically significant (Figure 3.39). At 
concentration of 0.1 mg/mL or less, the TA was still found to be relatively toxic 
compared to TA-NPs. However, regarding TA-NPs, around 80-100% viable cells 
were observed on TA NPs with TA concentration at 0.1 mg/mL or less, suggesting 
that the TA NPs did not induce toxicity on those concentration.  
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Figure 3.29: Effect of TA (1 mg/mL) and TA-NPs on ARPE 19 cell viability. 
Cells were seeded at 20,000 cells/well in DF12 media and exposed to 1 mg/mL of 
either TA or TA-NPs with drug concentration equivalent to TA for 24 hours. Cell 
viability was determined using MTT assay. Data represent mean ± SD (n=3).  
 
The toxicity of all TA NPs were significantly less than TA alone in ARPE 19 cells. 
Although only around 80% cells were viable after 24 hours exposure, NPs did not 
appear to induce toxicity.  
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Figure 3.30: Effect of TA (0.1 mg/mL) and TA-Nps on ARPE 19 cell viability. 
Cells were seeded at 20,000 cells/well in DF12 media and exposed to 0.1 mg/mL of 
either TA or TA-NPs with drug concentration equivalent to TA for 24 hours. Cell 
viability was determined using MTT assay. Data represent mean ± SD (n=3).  
 
Among three type of TA-NPs, TA-mPEG PLGA NPs was apparently the least toxic. 
The similar trend is also observed at the TA concentration of 0.1 mg/mL (Figure 
3.40), in which TA-mPEG PLGA NPs appeared to be the safest NPs. From the same 
figure, we revealed that the differences of cell viability after exposure to TA-PDLLA 
NPs and TA-PLGA NPs were statistically insignificant compared to cell viability 
after TA exposure.  
 
p= 0.017 
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Figure 3.31: Effect of empty NPs and TA-NPs on ARPE 19 cell viability. Cells 
were seeded at 20,000 cells/well in DF12 media and exposed to either TA-NPs with 
TA concentration of 1 mg/mL or empty NPs, for 24 hours. Cell viability was 
determined using MTT assay. Data represent mean ± SD (n=3).  
 
The toxicity of NP themselves were also assessed using ARPE 19. In comparison of 
the cell viability exposed to TA-NPs (which contain TA at 1 mg/mL) and empty 
NPs, it was revealed that there were no statistically significant differences between 
empty and TA-NPs  (Figure 3.41).  
 
To summarise, TA was found to be toxic at the highest concentration (1 mg/mL) on 
both cell models. Significant reduction of cell viability of cells was obtained in 
BALB/c 3T3 (down to 50%) and ARPE 19 (down to 60%). This finding is in 
agreement with other TA toxicity studies on ARPE 19 cell model 98, 110. The high 
toxicity level of TA on the highest concentration (1 mg/mL) was speculated to be 
due to substantially large particle size compared to the NPs. Szurman et al 111 
demonstrated that the cytotoxic effect of TA was governed by sedimented TA 
crystals or aggregates in direct contact with the cell surface. In addition to the results, 
BALB/c 3T3 cell viability reduction was found to be dose-dependent. They are also 
more sensitive to TA and TA NPs than ARPE 19.  
 
All types of TA-NPs were significantly less toxic than TA at the TA concentration of 
1 mg/mL on both cell models. The levels of cell viability after exposure to TA-NPs 
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were higher than those after exposure of TA. The differences of cell viability 
exposed to TA and TA-NPs were statistically significant (p<0.05). In addition, empty 
NPs and TA-NPs show the similar toxicity level, indicating that the cell viability of 
both cell culture models was less affected by NPs themselves. These findings suggest 
that the delivery of TA by NPs may potentially reduce the potential side effect of 
TA. Bejjani et al 112 demonstrated that PLGA NPs was considered to be non toxic 
upon RPE and its rapid internalization enables gene transfer and expression in RPE 
cells.  
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GENERAL DISCUSSION 
 
NP delivery was investigated for TA since it has potential advantages of providing 
controlled release and prolonging stability of TA. Moreover, due to their sub-micron 
size, NPs are more acceptable than larger particles for intra vascular administration 
as they are small enough for cellular internalization.   
 
TA was selected as a model for hydrophobic drugs for studying polymeric NP 
formulations. The control of particle size of hydrophobic drugs appears to be 
problematic in parenteral administration, since the hydrophobic particles tend to be 
physically unstable and aggregate. Polymeric NP formulations may provide 
alternatives to overcome these problems as surface of polymeric NPs can be readily 
modified. 
 
This study involves investigation of three types of polymers for incorporation of TA 
into NPs: poly (D,L, lactide) (PDLLA), poly (D,L, lactide-co-glycolide) (PLGA) and 
methoxy polyethyleneglycol-poly (D,L, lactide-co-glycolide) (mPEG-PLGA). PLGA 
is more hydrophilic than PDLLA due to the presence of glycolic acid on the 
copolymerisation of lactic acid with glycolic acid.  The hydrophilicity in mPEG 
PLGA is further enhanced by an addition of polyethyleneglycol group. The 
hydrophobicity level of those polymers follows this order: PDLLA > PLGA > 
mPEG-PLGA. 
 
4.1 Polymeric NP formulations for TA delivery 
Preparation of polymeric NPs was carried out by either the solvent diffusion or 
solvent evaporation method. The former method has an advantage of producing sub-
micron particles, using non toxic organic solvents, in an effective and reproducible 
manner 12, 47-49, 57, 58, 113. The latter method is commonly used to manufacture 
microparticles 15, 114. However, by appropriate modification NPs can also be easily 
made by this method.  One of the advantages of applying this method is that it 
provides high levels of yield, loading and entrapment efficiency, especially for 
hydrophobic drugs due to the slower evaporation of the organic solvent, which 
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results in slower precipitation of NPs. The difference which can be distinguished for 
both methods is the application of different solvent system. The solvent diffusion 
method involved acetone as the organic solvent, whereas in the solvent evaporation 
method, DCM which is immiscible with water, was employed instead of acetone. 
The solvent system in this study played an important role in determining the 
characteristics of NPs. 
 
The NPs were characterized for their particle size, surface charge, yield and loading 
value, and TA entrapment efficiency. An in vitro release study was conducted to 
investigate the release characteristics of all types of TA-NPs compared to TA control 
(free TA).  
 
The empty NPs made by both methods show excellent characteristics. Both methods 
can provide sub-micron particles with those made by the solvent diffusion method 
being smaller than those made by solvent evaporation. In terms of surface charge, the 
zeta potential of those particles was highly negative, indicating that NPs were well-
dispersed in the medium. In a comparison among polymers, PDLLA, which is the 
most hydrophobic polymer, exhibited the largest particle size, and the lowest yield. 
In the solvent diffusion method, this is due to a rapid diffusion of organic solvent 
into the aqueous stabiliser phase, leaving the polymer with strong hydrophobic bonds 
to associate, leading to aggregation and the formation of microparticles during NP 
preparation, which were not expected. Low concentration of the stabiliser in the 
solvent diffusion method (0.6% PVA) may have failed to effectively stabilise the 
emulsion, resulting in aggregation of polymer.  
 
Based on those characteristics, an attempt to incorporate 40 mg TA into 200 mg 
polymer was made using either solvent diffusion or solvent evaporation. To 
determine the concentration of TA, either for loading determination or release study, 
an HPLC method reported by Gupta74 was adopted with some modification to 
optimize the separation of the peaks. This method was selected since it provides a 
stability indicating assay for TA.  Validation of HPLC assay was conducted in order 
to develop an accurate and reproducible assay to determine TA concentration. The 
main parameters of validation such as: linearity of detector response, system 
precision, recovery (accuracy), sensitivity and selectivity, were examined. The 
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investigation revealed that the validated modified HPLC method developed in this 
study was suitable for the determination TA in the formulation and release 
experiments.  
 
Initially, solvent diffusion method was employed to prepare TA-loaded NPs with  
theoretical loading of 16.7%. The preparation of TA-PDLLA NPs, the entrapment 
efficiency initially appeared to be satisfactory (approximately 65%). However, 
further investigation showed that the NPs obtained were in a mixture of TA-NPs and 
TA crystals. An optimisation of the method therefore was conducted. By settling 
down the TA crystals for 30 minutes prior to PVA purification, the crystals were 
separated and removed from the NPs. It was found that by optimised solvent 
diffusion method, the yield, loading and entrapment efficiency of TA-NPs were 
extremely low. This was probably due to the high solubility of TA in acetone, as 
when acetone diffused out rapidly to the aqueous phase, TA also diffused out from 
the organic phase.   
 
The solvent evaporation method was then employed to prepare TA-NPs. In using this 
method, although the size was slightly increased, the yield, loading and entrapment 
efficiency of NPs made from three different polymers were obtained in reasonably 
high levels. The increased size was due to the primary droplet formed in the 
emulsification, which was affected by the concentration of polymer in organic 
solvent (the viscosity of organic phase).  The more viscous the organic phase, the 
larger the droplet. This is due to the less ability of the viscous organic phase to 
disperse. Eventually, larger droplet will produce larger NPs 96, 115. Slow evaporation 
of DCM also contributed to the formation of large particle size of NPs. However, the 
use of a sonicator during emulsification effectively reduce the size of NPs116. 
 
Görner et al115 demonstrated that an increase in size of the NPs would increase the 
entrapment efficiency. However, the initial amount of drug added plays an important 
role in determining the entrapment efficiency of NP preparation. In our study, 
although the size of TA-mPEG PLGA NPs (around 295 nm) was smaller than that of 
TA-PLGA NPs (around 325 nm), both TA-PLGA and TA-mPEG PLGA NPs 
exhibited high entrapment efficiency of around 65%. However, TA PDLLA NPs 
exhibited the largest size (around 360 nm) and the lowest entrapment efficiency 
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(30%). The low entrapment efficiency of TA-PDLLA NPs was probably due to the 
partitioning of polymer and TA between the dispersed and the dispersing phase. The 
partition is not only to the organic solvent as both polymer and drug molecule may 
also diffuse across the interface from organic phase to the external phase during NP 
formation 30.  
 
The preparation of NPs in this study involves PVA as a stabiliser.  Although PVA is 
reported as an effective stabiliser, which can assist to produce NPs with reduced size 
and high entrapment efficiency 36, 104, it is also reported by other investigator that 
PVA is a suspected carcinogen 105. Therefore, purification of NPs was carried out to 
remove the PVA. High speed centrifugation was selected as the purification 
technique due to its efficiency to separate the NPs from the supernatant containing 
PVA. Although high speed centrifugation offers satisfactory results in removing the 
PVA (Table 3.10 and Figure 3.11), PVA still could not be 100% removed from the 
system. This finding corresponds with the study reported by Murakami et al 48, 106 
which revealed that small amount of PVA appeared to be attached on the surface of 
NPs as a result of hydrophobic bonding.    
 
Physical stability of TA in NPs was also examined.  TA was extracted from TA-NPs 
after 96 hour-in vitro release study, and the extraction samples were injected into the 
HPLC. A typical chromatogram showed that no degradation product of TA was 
detected in the extraction (Figure 3.16). This finding was the same for all types of 
TA-NPs and suggests that TA was fully isolated by NPs from environmental hazards.  
 
In vitro release study was carried out only for the TA-NPs made by solvent 
evaporation, prone to small entrapment efficiency achieved by TA-NPs made by 
solvent diffusion. The release characteristics of three types of NPs show biphasic 
patterns. Initially, a fast constant release was observed over 8 hours (around 20% TA 
was released), followed by a slow release over 96 hours. The fast release of TA over 
8 hours was due to poor entrapment of TA resulting in reduced surface area. The 
slow release of TA after 24 hours might be performed by TA entrapped in the NPs.  
Of the three types of NPs, the greatest release was observed on TA-mPEG PLGA 
NPs, which were the smallest among those NPs (around 295 nm).             
Avgoustakis et al 53 demonstrated that the release of drug from mPEG PLGA NPs 
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was related to the mPEG content, it increases with an increase of mPEG content.  
The release characteristics of the NPs were normally governed by drug diffusion and 
polymer erosion, which is a result of polymer degradation. Porosity of the particles, 
as a result of solvent evaporation during initial preparation may also affect the  
release behaviour. The more porous the NPs, the higher the drug diffusion rate would 
be .  Hans and Lowman 12 reported that large particles would exhibit longer sustained 
release than small ones. They also illustrated that in terms of loading, the higher the 
loading may cause an increase in the release rate. From the investigation, it was 
found that TA- mPEG-PLGA with the highest loading (67%) show the fastest release 
( around 90% of TA released over 96 hours), while TA-PDLLA NPs with the particle 
sized around 360 nm, showed the slowest release among three types of NPs.   
 
Limitation of the formulation study 
There are several limitations in this study. Both methods used in the TA-NPs 
preparation could not produce NPs with size less than 200 nm. This is probably due 
to the relatively high polymer concentration in the organic phase. In terms of loading, 
the theoretical loading was too high (16.67%) to be loaded into the NPs resulting in 
very low entrapment efficiency and yield.   
 
4.2. In vitro toxicity study of TA-loaded NPs 
To assure the safety of polymeric NP formulations for TA delivery, it is essential that 
the toxicities of TA-NPs are assessed. Basic toxicity assessment of TA-NPs was 
carried out in this study upon two different cell lines: BALB/c 3T3 (fibroblasts) cells 
which are the immortalised and non malignant cells, and ARPE 19 (human retinal 
pigment epithelia) cells, which represent retinal cells. The toxicity was represented 
by percentage of cell viability of the samples over the control.  
 
 
In our study, we revealed that TA at 1 mg/mL was toxic. It reduced the cell viability 
of BALB/c 3T3 cell model down to 50% and ARPE 19 cell model down to 60%. 
However the TA-NPs containing the same amount of TA were less toxic than TA. In 
both cell models, it was found that BALB/c 3T3 cell model was more sensitive than 
ARPE 19. It also showed dose-dependent reduction in exposure to TA.   
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Although the effect of particle size of either TA or TA-NPs on the cell viability did 
not particularly investigated due to time limitation, the distinct difference of size 
between TA (microsize) and TA-NPs (nanosize) can be one of the reasons to explain 
the high toxicity of TA in this study. The possibility of TA crystals to be aggregated 
also contributed to the high potential of being toxic.  
 
Limitation of the in vitro toxicity study 
The MTT assay is an easy and simple assay and it is the best to be used with cells 
which show high mitochondrial activity. Cells with low mitochondrial activity may 
show low intensity leading to potential assay error.  
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CONCLUSION AND SCOPE FOR 
FUTURE WORK 
5.1 Conclusion 
The present study demonstrated that incorporation of TA into NPs with favourable 
characteristics can be achieved by solvent diffusion and solvent evaporation method 
using PDLLA, PLGA and mPEG PLGA. Although solvent diffusion produced NPs 
sized around 200 nm, which was less than of those made by solvent evaporation, 
solvent evaporation was superior to solvent diffusion method in terms of yield, 
loading and entrapment efficiency. In terms of NP characterization, TA NPs 
synthesized from mPEG PLGA exhibited the smallest particle size and the highest 
entrapment efficiency whereas PDLLA was more likely to produce particles with 
large size and low entrapment efficiency.  
 
All types of NPs studied demonstrated sustained release ability to certain degrees. 
This was particularly evident as the amount of the drug released reduced after 24 
hours and remained constant subsequently. TA-mPEG NPs, which has the highest 
drug loading exhibited the fastest release, while TA-PDLLA NPs appeared to release 
TA in the slowest rate.  
 
Stability of TA in NPs was found to be superior to that in drug suspension. 
Undetected degradation products in TA-NPs over 96 hours, indicated that the 
stability of TA has been enhanced by NP formulations. 
 
An in vitro toxicity study revealed that in both BALB/c 3T3 and ARPE 19 cells, TA 
was toxic on the highest concentration (1 mg/mL) while the TA-NPs containing TA 
at the same concentration, were less likely to be toxic. The difference of cell viability 
determined under exposure of either TA loaded- NPs or blank NPs was found to be 
statistically insignificant (p>0.05), indicating that the components of NPs beside the 
drug did not induce toxicity. BALB/c 3T3 cells were more sensitive than ARPE 19 to 
TA and TA-NPs.   
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In summary, the TA NPs which were made from biodegradable and biocompatible 
polymers, have shown a promising delivery for TA, in which NPs provide controlled 
release properties,  are potential to reduce the toxicity of TA,  and are able to prolong 
the stability of TA.  
 
5.2 Scope for future work 
Although TA loaded NPs were successfully made by a simple solvent evaporation 
method, the ideal manufacture of NPs has not been achieved due to the use of a toxic 
organic solvent and a potentially toxic stabiliser. The method conducted in this study, 
failed to produce the NPs with size less than 200 nm.  It will be worthwhile to 
investigate the preparation parameters of NPs which can produce small NPs (< 200 
nm) and can be potentially scaled up with high drug loading and yield. The polymer 
which has a nature like mPEG-PLGA is considered to be a suitable polymer for NP 
manufacture since it is biocompatible and able to prolong the circulation of NPs.  
 
The mechanism of release study of TA-NPs needs to be investigated further. The 
experimental conditions for the in vitro release study should be further optimised to 
ensure sink conditions in the system. As for the formulation, an additional feature 
which can minimize burst release should be taken into consideration in the design of 
the formulations.    
 
The properties to be available for cellular uptake have become focus to explore in the 
preparation of NPs. Since TA-NPs considered to be less toxic than TA itself, it will 
be worthwhile to study the mechanism of cellular traffic of TA-NPs to understand 
the distribution and interaction of NPs with the biological system.  
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APPENDIX 
 
Appendix 1: A sample of LOD/LOQ calculation 
Noise :
Injection No. Noise (6SD)
1 0.044 LOD
2 0.052 = (3 x Average of noise SD) : slope of std Conc vs height
3 0.032 = 0.053 (μg/ml)
4 0.036
5 0.037 LOQ
6 0.055 = (10 x Average of noise SD) : slope of std Conc vs height
Average 0.042 = 0.18 (μg/ml)
SD 0.009
Linearity of detector response
y = 2.3913x + 0.1243
R2 = 1
0
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Appendix 2: Purity factor of TA peak on HPLC assay 
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Appendix 3: Data of TA potency and degradation products 
(a) TA stability in ACN: mobile phase 1:1 over 72 hours  
at three different temperatures  
 Time (h) Potency (%)* Degradation product (%) 
4ºC 25ºC 37ºC 4ºC 25ºC 37ºC 
0 100.00 100.00 100.00 0.00 0.00 0.00 
3 100.00 99.19 99.44 0.00 0.81 0.56 
6 99.62 98.68 98.54 0.38 1.32 1.46 
9 100.00 98.84 97.98 0.00 1.16 2.02 
24 100.00 98.77 96.33 0.00 1.23 3.67 
72 95.88 95.48 97.31 4.12 4.52 2.69 
 
 (b) TA stability in PBS pH 7.4 over 72 hours  
at three different temperatures  
Time 
(h) 
Potency (%)* Degradation product (%) 
4ºC 25ºC 37ºC 4ºC 25ºC 37ºC 
0 100.00 100.00 100.00 0.00 0.00 0.00 
3 97.90 97.37 95.68 2.10 2.63 4.32 
6 97.33 96.46 94.53 2.67 3.54 5.47 
9 99.00 98.00 94.29 1.00 2.00 5.71 
24 97.21 92.80 84.49 2.79 7.20 15.51 
72 95.73 88.44 60.23 4.27 11.56 39.77 
 
(c) TA stability in PBS-NaN3 over 72 hours  
at three different temperatures 
Time 
(h) 
Potency (%)* Degradation product (%) 
4ºC 25ºC 37ºC 4ºC 25ºC 37ºC 
0 100.00 100.00 100.00 0.00 0.00 0.00 
3 96.56 97.84 95.67 3.44 2.16 4.33 
6 95.57 94.81 93.40 4.43 5.19 6.60 
9 99.24 97.71 92.88 0.76 2.29 7.12 
24 96.82 93.95 82.03 3.18 6.05 17.97 
72 93.60 85.63 57.05 6.40 14.37 42.95 
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Appendix 4: SEM image of PDLLA NPs made by solvent diffusion method 
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Appendix 5: Turbidity data 
 
Time 
(min) 
Absorbance 
TA PDLLA mPEG PLGA 
0 0.003 3.786 3.767 
2 0.015 3.889 3.806 
5 0.389 3.603 3.697 
10 0.370 3.852 3.842 
15 0.309 3.994 3.999 
20 0.268 3.555 3.690 
25 0.379 3.903 3.920 
30 0.350 3.727 3.998 
 
 110
Appendix 6:  Particle measurement by FESEM on TA-MPEG PLGA 
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Appendix 7: Solubility data of TA in PBS-NaN3 pH 7.4 
 
Time (hour) Solubility (μg/mL) 
8 6.58 ± 1.20 
24 27.40 ± 0.40 
48 28.06 ± 0.82 
 
